CELL-FREE PRODUCTION OF CARMINIC ACID

Abstract
The invention is related to materials and methods for production of carminic acid from substrates. The invention provides methods and materials for cell-free bioproduction of carminic acid.
Description
I. FIELD OF INVENTION

The invention is related to materials and methods for production of carminic acid. The invention provides methods and materials for cell-free production of carminic acid.


II. REFERENCE TO SEQUENCE LISTING

The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file named DEBU-020-01US.xml, created on Jun. 26, 2024, which is 56 kilobytes in size. The information in the electronic format of the Sequence Listing is incorporated herein by reference in its entirety.


III. BACKGROUND

Carminic acid is used as an additive in food. Carminic acid is one of the most frequently used dyes in food, medicine, cosmetics and textiles. Carminic acid is added to foods such as ketchup, strawberry milk, and candies. It is also added to cosmetics such as eye shadow, nail polish and lipstick.


Carminic acid is a colorant, which can be extracted from the female insect bodies of Dactylopius coccus costa (alternative name Coccus cacti L.). The insects live on Nopalea coccinellifera, Opuntia fidus indica and other plants of the family Cactaceae cultivated for instance in the desert areas of Mexico, Central and South America and Canary Islands. Depending on the pH the colorant may be a color in a spectrum from orange over red to purple and is generally known as cochineal or cochineal color. Carmine colorant is widely used in foods and beverages.


In relation to current industrial relevant production, carminic acid is harvested by extraction from the insect's dried bodies with water or alcohol. The insects (Dactylopius coccus) are cultured on cacti.


IV. SUMMARY OF THE INVENTION

The conventional methods of industrial production of carminic acid involves extraction of carminic acid from insect's bodies. In some other convention methods of production of carminic acid, the production of carminic acid may be conducted inside a host organisms and/or cells. As a result, the supply may therefore be relatively expensive and subject to undesirable variations and price fluctuations. The invention provides methods and compositions for cell-free production of carminic acid. The methods provided in the invention related to cell-free production of carminic acid are economic and reliable as compared to other conventional methods of production of carminic acid. In addition, the methods provided in the invention provide higher titer values of the carminic acid from these processes as compared to carminic acid produced from other conventional methods.


In one aspect, the invention provides a cell-free production of carminic acid, wherein the method comprises: providing one or more enzymes in a cell-free medium, wherein the one or more enzymes result in transformation of one or more substrates to carminic acid. In certain embodiments, the substrate that is converted to carminic acid is kermesic acid. In certain embodiments, the enzyme that transforms kermesic acid to carminic acid is C-glucosyltransferase (CGT). In certain embodiments, the reaction medium for C-glucosyltransferase (CGT) mediated enzymatic transformation of kermesic acid to carminic acid further comprises an activated sugar. In certain embodiments, the activated sugar is uridine diphosphate glucose (UDP-glucose). In certain embodiments, UDP-glucose is an essential co-factor for the transformation of kermesic acid to carminic acid. An overview of the conversion of kermesic acid to carminic acid is provided in FIG. 1.


In certain aspects, the activated sugar and/or UDP-glucose is added to the reaction medium. In certain aspects, the activated sugar in the reaction medium for cell-free production of carminic acid is UDP-glucose. In certain embodiments, the UDP-glucose for the reaction medium is generated from sucrose. In certain embodiments, the UDP-glucose is generated in the reaction medium by one or more enzymes. In certain embodiments, the generation of UDP-sugar is mediated by sucrose synthase (SuSy). In certain embodiments, sucrose synthase (SuSy) mediates the conversion of sucrose to UDP-glucose. Thus, in certain embodiments, the reaction medium comprises sucrose, which is subsequently converted to UDP-glucose in course of the reaction. An overview of the process where kermesic acid is converted to carminic acid and UDP-glucose is generated from sucrose is provided in FIG. 2.


In certain beneficial aspects, the invention provides that the UDP-glucose used in the reaction is generated from other substrates in course of the reaction. In certain embodiments, the UDP moiety in UDP-glucose is recycled in course of the process. The recycling of UDP provides economic efficiency of the processes of the invention. Accordingly, in certain aspects, the production of carminic acid from kermesic acid catalyzed by CGT is conducted in conjunction with other methods for UDP-glucose production or recycling of UDP. In certain embodiments, the overview of the synthetic scheme involving the UDP-glucose production and/or recycling is provided in FIG. 3. In certain embodiments, UDP-glucose is generated by the reaction of uridine triphosphate (UTP) with glucose-1-phosphate. In certain preferred embodiments, the reaction of UTP and glucose-1-phosphate is catalyzed by UTP-glucose-1-phosphate uridylyltransferase (UGP). In certain preferred embodiments, the UGP may be galU.


In certain aspects, glucose-1-phosphate is the source for formation of UDP-glucose. Accordingly, in certain embodiments, glucose-1-phosphate may be added to the reaction for generation of carminic acid. In certain embodiments, the glucose-1-phosphate may be supplied to the reaction for preparation of carminic acid.


In certain embodiments, glucose-1-phosphate is generated during the course of the reaction. In certain embodiments, glucose-1-phosphate is generated enzymatically during the course of the reaction. Accordingly, in certain embodiments, glucose is converted to glucose-6-phosphate by a reaction of ATP (adenosine triphosphate) and glucose. In certain embodiments, reaction between glucose and ATP results in generation of glucose-6-phosphate and adenosine diphosphate (ADP). In certain embodiments, conversion of glucose to glucose-6-phosphate is catalyzed by glucokinase (GLK). In certain embodiments, conversion of glucose to glucose-6-phosphate is catalyzed by hexokinase (HK). In certain embodiments, glucose-6-phosphate is converted to glucose-1-phosphate. In certain embodiments, the conversion of glucose-6-phosphate to glucose-1-phsophate is catalyzed by phosphoglucomutase (PGM).


In certain aspects, the invention further provides that the nucleoside triphosphate species used in the reaction are recycled. In certain embodiments, the recycled nucleoside trisphosphates are ATP and UTP. In certain embodiments, UTP is generated by reaction of UDP and ATP. In certain embodiments, the generation of UTP from UDP and ATP is catalyzed by nucleoside diphosphate kinase (NDK). In certain embodiments, ATP may be generated from ADP and phosphate or polyphosphate. In certain embodiments, the conversion of ADP to ATP is catalyzed by polyphosphate kinase (PPK).


In certain beneficial aspects, the invention provides that the processes of the invention are cost effective because of the recycling of chemical intermediates involved in the reaction. In certain embodiments, the invention provides that chemical intermediates like UDP-glucose, UDP, and glucose-1-phosphate are recycled. Indeed, in certain embodiments, the only reagents required in non-catalytic quantities for the production of carminic acid by conversion of kermesic acid are polyphosphate/phosphate and glucose. Because the processes provided in the invention are conducted in a cell free medium and the ingredients (required in non-catalytic quantities) are economic, the processes of the invention are cost effective.


In certain aspects, the one or more enzymes required for the cell-free production of carminic acid are expressed in a host organism. In certain embodiments, the host organism is selected from a group consisting of: bacteria, yeast, and/or mammalian cells. In certain embodiments, the one or more enzymes are introduced in the host organism by integration into genome of the host organism or on a plasmid. In certain embodiments, the plasmid comprises extrachromosomal DNA, which can be expressed by the host organism. In certain embodiments, host organisms expressing the one or more enzymes are cultured until a pre-determined biomass is achieved to produce the requisite quantity of the one or more enzymes. The predetermined biomass is calculated based on the quantity of the one or more enzymes required for the cell-free production of carminic acid. In certain embodiments, the culture comprising host organisms expressing the one or more enzymes are lysed and used as the reaction medium for the methods provided in the invention. In certain other embodiments, once the culture comprising host organisms is lysed, the cell-debris is removed from the lysed matter to prepare the reaction medium for the methods of the invention.


In certain embodiments, the one or more enzymes expressed in the host cells are C-glucosyltransferase (CGT) and/or sucrose synthase (SuSy). In certain embodiments, C-glucosyltransferase (CGT) and/or sucrose synthase (SuSy) are present in the cell-free medium for the cell-free production of carminic acid.


In certain embodiments, the one or more enzymes expressed in host cells are C-glucosyltransferase (CGT), sucrose synthase (SuSy), glucokinase (GLK), hexokinasc (HK), phosphoglucomutase (PGM), polyphosphate kinase (PPK), UTP-glucose-1-phosphate uridylyltransferase (UGP), and/or nucleoside diphosphate kinase (NDK). In certain embodiments, C-glucosyltransferase (CGT), sucrose synthase (SuSy), glucokinase (GLK), hexokinase (HK), phosphoglucomutase (PGM), polyphosphate kinase (PPK), UTP-glucose-1-phosphate uridylyltransferase (UGP), and/or nucleoside diphosphate kinase (NDK) are present in the cell-free medium for the cell-free production of carminic acid.


In certain embodiments of the invention, the reaction mixture comprises purified enzymes for the cell-free production of carminic acid. In certain embodiments, the purified enzymes are C-glucosyltransferase (CGT), sucrose synthase (SuSy), glucokinase (GLK), hexokinase (HK), phosphoglucomutase (PGM), polyphosphate kinase (PPK), UTP-glucose-1-phosphate uridylyltransferase (UGP), and/or nucleoside diphosphate kinase (NDK). In certain embodiments, C-glucosyltransferase (CGT), sucrose synthase (SuSy), glucokinase (GLK), hexokinase (HK), phosphoglucomutase (PGM), polyphosphate kinase (PPK), UTP-glucose-1-phosphate uridylyltransferase (UGP), and/or nucleoside diphosphate kinase (NDK) are not purified. In certain embodiments, the purified enzymes are C-glucosyltransferase (CGT) and/or sucrose synthase (SuSy).


In certain embodiments, the one or more enzymes to produce carminic acid is glucosyltransferase (GT) and/or C-glucosyltransferase (CGT). In certain embodiments, GT and/or CGT used for cell-free production of carminic acid is selected from the enzymes having at least 80% amino acid sequence identity from the enzymes provided in Table 1 below. In certain embodiments, GT and/or CGT used for cell-free production of carminic acid is selected from the enzymes having at least 95% amino acid sequence identity from the enzymes provided in Table 1 below.












TABLE 1







Accession #
Organism









AXF38108

Bergenia purpurascens




AFJ52990

Linum usitatissimum




KAG8368435

Buddleja alternifolia




AFJ52991

Linum usitatissimum




AUI41123

Rhodiola rosea




KAD6795309

Mikania micrantha




XP_006282251

Capsella rubella




BAF18172

Oryza sativa Japonica Group




A0A0B6VIJ5

Gentiana trifloral




GKV43195.1

Shorea leprosula




CAA7037192.1

Microthlaspi erraticum




CAD6239704.1

Miscanthus lutarioriparius




XP_021750757

Chenopodium quinoa




BAG14302

Gomphrena globose




XP_031382117

Punica granatum











In certain embodiments, the one or more enzymes involved in production of UDP-glucose, which is an ingredient in the cell-free production of carminic acid is sucrose synthase (SuSy). In certain embodiments, SuSy used for production of UDP-glucose is selected from the enzymes having at least 80% amino acid sequence identity from the enzymes provided in Table 2 below. In certain embodiments, SuSy used for production of UDP-glucose is selected from the enzymes having at least 95% amino acid sequence identity from the enzymes provided in Table 2 below.












TABLE 2







Accession #
Organism









WP_004872341.1

Acidithiobacillus caldus




P30298.2

Oryza sativa Japonica Group




Q820M5.1

Nitrosomonas europaea ATCC 19718




P13708.2

Glycine max




CAA09297.1

Nostoc sp. PCC 7119




P49036.1

Zea mays




P49040.3

Arabidopsis thaliana




Q9M111.1

Arabidopsis thaliana




Q8W517

Ipomoea batatas




WP_011056890

Thermosynechococcus elongatus











In certain embodiments, the one or more enzymes involved in generation of UDP-glucose and/or recycling of one or more reaction intermediates are provided below. In certain embodiments, the enzymes used for generation of UDP-glucose (by reaction with UTP) and/or recycling of one or more intermediates are selected from the enzymes having at least 95% amino acid sequence identity from the enzymes provided in Table 3 below.












TABLE 3







Enzyme
Accession No.









GLK
AAA27694.1



GLK
WP_331012003.1



PGM
AAC73782.1



PGM
A0A110EI47



PGM
A0A7M2S2U2



UGP
EEW2752841.1



UGP
WP_021648042.1



UGP
WP_028847555.1



NDK
WP_000963837.1



NDK
CAF21035.1



NDK
WP_066795798



PPK2
WP_010968631



PPK2
WP_160857702










In certain embodiments, the invention provides engineered GT/CGT/SuSy enzymes for the cell-free production of carminic acid. In certain embodiments, the engineered GT/CGT/SuSy enzymes were optimized for cell-free production of carminic acid. In certain embodiments, engineered GT/CGT/SuSy enzymes may include genetic modifications. In certain embodiments, the genetic modifications may be selected from a group consisting of: point mutations, insertions, deletions, and/or any other modifications such that those enzymes result in efficient and optimal cell-free production of carminic acid. In certain embodiments, the GT/CGT/SuSy enzymes used in the cell-free production of carminic acid are any enzymes disclosed in this application.


In certain aspects of the invention, the method of the cell-free production does not require the purification of the one or more enzymes from the lysed host organisms. In certain embodiments, the methods of the invention do not require the purification of one or more enzymes from the lysed biomass comprising host cell expressing the one or more enzymes for the cell-free production of carminic acid. In certain embodiments, the methods of the invention do not require the purification of C-glucosyltransferase (CGT), sucrose synthase (SuSy), glucokinase (GLK), hexokinase (HK), phosphoglucomutase (PGM), polyphosphate kinase (PPK), UTP-glucose-1-phosphate uridylyltransferase (UGP), and/or nucleoside diphosphate kinase (NDK). In certain embodiments, the methods of the invention do not require the purification of C-glucosyltransferase (CGT) and/or sucrose synthase (SuSy) from the lysed cells for cell-free production of carminic acid. This is advantageous because it increases the efficiency of the method and reduces the costs associated with the purification of these enzymes.


In certain embodiments, the cell-free medium may further comprise any other additional ingredients required for the cell-free production of carminic acid. In certain embodiments, the cell-free medium comprises buffer, kermesic acid, an activated sugar, magnesium chloride, cell lysate, sucrose, glucose, glucose-1-phosphate, glucose-6-phosphate, UDP, UTP, ATP, polyphosphate, and/or water. In certain embodiments, the cell-free medium comprises buffer, kermesic acid, an activated sugar, magnesium chloride, cell lysate, sucrose, and/or water. In certain embodiments, the buffer used in the cell-free reaction medium is any buffer suitable for enzymatic conversion of kermesic acid to carminic acid. In certain embodiments, the buffer maintains the pH of about 5 to about 9 in the reaction mixture. In certain embodiments, the buffer maintains the pH of about 6 to about 8 in the reaction mixture. In certain embodiments, the buffer maintains the pH in the range of 6 to 8 in the reaction mixture. In certain embodiments, the buffer is a phosphate buffer. In certain embodiments, the buffer is present at a concentration of about 1 mM to about 200 mM. In certain embodiments, the buffer is present at a concentration of about 5 mM to about 100 mM.


In certain embodiments, the cell-free reaction medium comprises activated sugar at a concentration of about 0.001 mM to about 50 mM. In certain embodiments, the cell-free reaction medium comprises activated sugar at a concentration of about 0.01 mM to about 10 mM. In certain embodiments, the cell-free reaction medium comprises activated sugar at a concentration of about 0.01 mM to about 5 mM. In certain embodiments, the activated sugar is UDP-glucose.


In certain embodiments, the cell-free reaction medium comprises magnesium chloride at a concentration of about 0.5 mM to about 40 mM. In certain embodiments, the cell-free reaction medium comprises magnesium chloride at a concentration of about 1 mM to about 20 mM.


In certain embodiments, the cell-free reaction medium further comprises sucrose. In certain embodiments, the sucrose is converted to UDP-glucose. Thus, the concentration of sucrose in the reaction mixture is determined by the quantity of UDP-glucose needed for the reaction for cell-free production of carminic acid. In certain embodiments, sucrose is present at a concentration of about 10 mM to about 1000 mM in the cell-free reaction medium. In certain embodiments, sucrose is present at a concentration of about 20 mM to about 800 mM in the cell-free reaction medium. In certain embodiments, sucrose is present at a concentration of about 50 mM to about 600 mM in the cell-free reaction medium.


In certain embodiments, the quantity of the one or more enzymes for the cell-free production of carminic acid is dependent on the target quantity of carminic acid to be produced and/or the concentration of other ingredients present in the reaction mixture. In certain embodiments, the one or more enzymes are present in a concentration of from about 1% to about 50% (v/v). In certain embodiments, the one or more enzymes are present in a concentration of from about 2.5% to about 45% (v/v). In certain embodiments, the one or more enzymes are present in a concentration of from about 5% to about 40% (v/v). In certain embodiments, the one or more enzymes are present in a concentration of from about 7.5% to about 30% (v/v).


In certain embodiments, the reaction for production of carminic acid is conducted for a duration till the desired quantity of carminic acid is obtained. In certain embodiments, the reaction for cell-free production of carminic acid is carried out from about 10 minutes to about 48 hours. In certain embodiments, the reaction for cell-free production of carminic acid is carried out from about 10 minutes to about 36 hours. In certain embodiments, the reaction for cell-free production of carminic acid is carried out from about 20 minutes to about 24 hours. In certain embodiments, the reaction for cell-free production of carminic acid is carried out from about 30 minutes to about 20 hours. In certain embodiments, the reaction for cell-free production of carminic acid is carried out from about 1 hour to about 15 hours.


In certain embodiments, the temperature of the reaction mixture for cell-free production of carminic acid is varied to obtain optimal results for the production of carminic acid. In certain embodiments, the temperature of the reaction mixture for cell-free production of carminic acid is from about 15° C. to about 45° C. In certain embodiments, the temperature of the reaction mixture for cell-free production of carminic acid is from about 20° C. to about 40° C. In certain embodiments, the temperature of the reaction mixture for cell-free production of carminic acid is from about 22.5° C. to about 37.5° C. The temperature of the reaction mixture for cell-free production of carminic acid may influence the rate of production of carminic acid. Consequently, the duration of reaction may be adjusted according to the temperature of the reaction mixture to obtain optimal yield of carminic acid in cell-free production of carminic acid.


In certain aspects, the methods provided in the invention may be carried out in any reactor suitable for carrying out the cell-free production of carminic acid. In certain embodiments, the reaction for cell-free production of carminic acid is conducted in a bubble column reactor/bioreactor. In certain embodiments, in the bubble column reactor/bioreactor, the one or more enzymes involved in cell-free production of carminic acid are in a solution. In certain embodiments, the reaction for cell-free production of carminic acid is conducted in a bubble column reactor/bioreactor comprises the lysate from the host organism. In certain embodiments, it is advantageous to use the bubble column reactor/bioreactor for cell-free production of carminic acid when the reaction mixture involves the lysate (or lysate with cellular debris removed) from the host cell organisms in which the one or more enzymes responsible for cell-free production of carminic acid were utilized. In certain embodiments, the reaction for cell-free production of carminic acid is conducted in a packed bed reactor/bioreactor. In certain embodiments, the one or more enzymes are immobilized in the packed bed reactor/bioreactor. The packed bed reactors/bioreactors are preferred for the purified enzymes playing a role in cell-free production of carminic acid. In certain embodiments, the one or more enzymes may be immobilized in a single reactor/bioreactor. In certain other embodiments, the one or more enzymes may be immobilized in different reactors/bioreactors, wherein these reactors/bioreactors are linked sequentially.


The methods provided in the invention are advantageous over other conventional methods of production of carminic acid. In certain embodiments, the methods of the invention provide cell-free production of carminic acid. Because the methods of the invention are conducted in cell-free medium, they provide significant economic efficiency by reducing the cost of production of carminic acid in other conventional methods. In certain embodiments, because the reaction for production of carminic acid is conducted from the lysates from the host organisms expressing the one or more enzymes involved in the reaction, the methods of the invention are cost-efficient. In particular, in certain embodiments, the methods of the invention do not involve the purification of the one or more enzymes. Because purification of individual enzymes is not required in the methods of the invention, provides further economic efficiency by reducing the cost that would have been otherwise required in purifying individual enzymes.


Advantageously, the cell-free production of carminic acid provided herein provides a significantly higher titer value for carminic acid as compared to the conventional methods. The higher titer values of carminic acid provide additional cost advantages for production of carminic acid because the higher titer carminic acid would provide efficiency in purifying and/or concentrating carminic acid from the reaction mixture. In certain embodiments, the methods of the invention provide carminic acid titer value of from at least 5-fold higher than the conventional methods. In certain embodiments, the methods of the invention provide carminic acid titer value of from at least 10-fold higher than the conventional methods. In certain embodiments, the methods of the invention provide carminic acid titer value of from at least 50-fold higher than the conventional methods. In certain embodiments, the methods of the invention provide carminic acid titer value of from at least 100-fold higher than the conventional methods. In certain embodiments, the methods of the invention provide carminic acid titer value of from at least 500-fold higher than the conventional methods. In certain embodiments, the methods of the invention provide carminic acid titer value of from at least 1000-fold higher than the conventional methods. In certain embodiments, the methods of the invention provide carminic acid titer value of from at least 5000-fold higher than the conventional methods.


In certain aspects, the invention provides compositions for cell-free production of carminic acid. The compositions of the invention are utilized for cell-free production of carminic acid in accordance with the methods described above.


In certain embodiments, the compositions of the invention comprise: one or more enzymes in a cell-free medium, wherein the one or more enzymes result in transformation of a substrate to carminic acid. In certain embodiments, the substrate converted to carminic acid is kermesic acid. In certain embodiments, the one or more enzyme is C-glucosyltransferase (CGT). In certain embodiments, the compositions further comprise a cell-free medium. In certain embodiments, the cell-free medium comprises an activated sugar. In certain embodiments, the activated sugar is UDP-glucose. In certain embodiments, the UDP-glucose is added to the cell-free medium.


In certain aspects of the invention, the UDP-glucose in the composition is synthesized in the cell-free medium by the one or more enzymes. In certain embodiments, the UDP-glucose is synthesized from sucrose. In certain embodiments, the one or more enzymes is sucrose synthase (SuSy) that synthesizes UDP-glucose from sucrose. In certain embodiments, the cell-free medium is a cell lysate. In certain embodiments, the cell lysate is a cell lysate from cells from a host organism expressing the one or more enzymes. In certain embodiments, the host organism is selected from a group consisting of: bacteria, yeast, and/or mammalian cells. In certain embodiments, the one or more enzymes are introduced in the host organism by integration into genome of the host organism or on a plasmid. In certain embodiments, the host organisms expressing the one or more enzymes are cultured until a pre-determined biomass is achieved to produce the requisite quantity of the one or more enzymes. In certain embodiments, the composition further comprises cell lysate generated by lysis of cells and subsequent removal of cell debris, for use in the cell-free medium for cell-free production of carminic acid.


In certain embodiments, the CGT, SuSy, GLK, HK, PGM, PPK, UGP, and/or NDK enzymes are present in the cell-free medium for cell-free production of carminic acid. In certain embodiments, the compositions of the invention provide CGT, SuSy, GLK, HK, PGM, PPK, UGP, and/or NDK that have not been purified or separated.


In certain embodiments, the CGT and SuSy enzymes are present in the cell-free medium for cell-free production of carminic acid. In certain embodiments, the compositions of the invention provide CGT and SuSy that have not been purified or separated.


In certain embodiments, the cell-free medium may further comprise any other additional ingredients required for the cell-free production of carminic acid. For example, in certain embodiments, the cell-free medium comprises buffer, kermesic acid, an activated sugar, magnesium chloride, cell lysate, sucrose, and/or water. In certain embodiments, the buffer used in the cell-free reaction medium is any buffer suitable for enzymatic conversion of kermesic acid to carminic acid. In certain embodiments, the buffer maintains the pH of about 5 to about 9 in the reaction mixture. In certain embodiments, the buffer maintains the pH of about 6 to about 8 in the reaction mixture. In certain embodiments, the buffer maintains the pH in the range of 6 to 8 in the reaction mixture. In certain embodiments, the buffer is a phosphate buffer. In certain embodiments, the buffer is present at a concentration of about 1 mM to about 200 mM. In certain embodiments, the buffer is present at a concentration of about 5 mM to about 100 mM.


In certain embodiments, the cell-free reaction medium comprises activated sugar at a concentration of about 0.001 mM to about 50 mM. In certain embodiments, the cell-free reaction medium comprises activated sugar at a concentration of about 0.01 mM to about 5 mM. In certain embodiments, the activated sugar is UDP-glucose.


In certain embodiments, the cell-free reaction medium comprises magnesium chloride at a concentration of about 0.5 mM to about 40 mM. In certain embodiments, the cell-free reaction medium comprises magnesium chloride at a concentration of about 1 mM to about 20 mM.


In certain embodiments, the cell-free reaction medium further comprises sucrose. In certain embodiments, the sucrose is converted to UDP-glucose. Thus, the concentration of sucrose in the reaction mixture is determined by the quantity of UDP-glucose needed for the reaction for cell-free production of carminic acid. In certain embodiments, sucrose is present at a concentration of about 10 mM to about 1000 mM in the cell-free reaction medium. In certain embodiments, sucrose is present at a concentration of about 20 mM to about 800 mM in the cell-free reaction medium. In certain embodiments, sucrose is present at a concentration of about 50 mM to about 600 mM in the cell-free reaction medium.


In certain embodiments, the quantity of the one or more enzymes for the cell-free production of carminic acid is dependent on the target quantity of carminic acid to be produced and/or the concentration of other ingredients present in the reaction mixture. In certain embodiments, the one or more enzymes are present in a concentration of from about 1% to about 50% (v/v). In certain embodiments, the one or more enzymes are present in a concentration of from about 2.5% to about 45% (v/v). In certain embodiments, the one or more enzymes are present in a concentration of from about 5% to about 40% (v/v). In certain embodiments, the one or more enzymes are present in a concentration of from about 7.5% to about 30% (v/v).


In certain aspects of the invention, the compositions of the invention are in a bubble column reactor, wherein the one or more enzymes are in a solution. In certain embodiments, the compositions of the invention are in a packed bed reactor, wherein the one or more enzymes are immobilized.





V. BRIEF DESCRIPTION OF FIGURES


FIG. 1 provides a schematic of conversion of kermesic acid to carminic acid.



FIG. 2 provides a schematic of the reaction scheme showing the conversion of kermesic acid to carminic acid, and the conversion of sucrose to UDP-glucose.



FIG. 3 provides a schematic of the reaction scheme showing the conversion of kermesic acid to carminic acid, wherein the UDP is recycled.



FIG. 4 provides HPLC chromatograms demonstrating the conversion of kermesic acid to carminic acid in a cell-free medium upon addition of CGT and UDP-glucose in the reaction mixture.





VI. DETAILED DESCRIPTION

The present application provides compositions and methods for production of carminic acid in a cell-free medium, wherein one or more enzymes in a cell-free medium, wherein the one or more enzymes result in transformation of an organic material to carminic acid. The one or more enzymes may be engineered. The engineered enzyme may be non-naturally occurring.


The term “non-naturally occurring”, when used in reference to an enzyme is intended to mean that nucleic acids or polypeptides include at least one genetic alteration not normally found in a naturally occurring polypeptide or nucleic acid sequence. Naturally occurring nucleic acids, and polypeptides can be referred to as “wild-type” or “original”. A host cell, organism, or microorganism that includes at least one genetic modification generated by human intervention can also be referred to as “non-naturally occurring”, “engineered”, “genetically engineered,” or “recombinant”.


As used herein, the singular forms “a,” “an,” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. Furthermore, to the extent that the terms “including,” “includes,” “having,” “has,” “with,” or variants thereof are used in either the detailed description and/or the claims, such terms are intended to be inclusive in a manner similar to the term “comprising.”


As used herein, “reaction solution” may refer to all components necessary for enzyme-based chemical transformation. This is typically, but not limited to, buffering agent, salts, cofactor, and substrate (starting material).


As used herein, “reaction mixture” may refer to all components from the “reaction solution” plus the enzyme(s) and/or products from the reaction. In some embodiments, the “reaction mixture” may refer to just the reaction solution without any enzymes or reaction products. In some embodiments, “reaction solution” and “reaction mixture” may be used interchangeably.


As used herein, “buffering agents” may refer to chemicals added to water-based solutions that resist changes in pH by the action of acid-base conjugate components.


As used herein, “cofactors” may refer to a non-protein chemical compound that may bind to a protein and assist with a biological chemical reaction. Non-limiting examples of cofactors may include but are not limited to NADPH and NADH.


In the cell-free systems described herein, the critical components of the cell, namely cofactors and enzymes, are used in a chemical reaction without cellular components that can directly or indirectly inhibit the desired biochemical reaction. The same enzymes found in plants and other organisms may be created in vivo (typically through protein overexpression in hosts such as bacteria), isolated via chromatography and/or any other methods, and then added into a bioreactor with a substrate (starting material). The enzymes may also be used directly from plants without any isolation. The enzymes transform the substrate in the same way that occurs in the original organism without the organism's complexity. Additionally, the biochemical reaction may be enhanced by the addition of co-solvents, detergents, or both, which would not be tolerated by, or simply would not work in a whole cell-based manufacturing method. In this way, natural products can be created without the plant, cell, or chemical synthesis.


Carminic Acid:

Carminic acid is used in edible food colorants. Carminic acid is an anthraquinone compound containing a glucose molecule attached via a glycosidic bond. Unsaturated rings in the anthraquinone portion strongly absorb light and are responsible for its intense purple color. Depending on the pH the colorant may be a color in a spectrum from orange over red to purple and is generally known as cochineal or cochineal color. Carmine is the most used form of carminic acid. Carminic acid and derivatives are found in a large range of food such as ice cream, confectionery, culinary, desserts, beverages, dairy and others. Carmine is also widely used in cosmetics. Carmine is a highly stable pigment that can reasonably withstand heat processing and adverse storage conditions. Carmine, the most used form of carminic acid, is obtained by adding aluminum sulphate in basic conditions to the cochineal extract. This produces a complexation of carminic acid to the metal that cause a bathochromic shift that after sol-gel polymerization gives an insoluble red lake formulation.


The widespread use of carminic acid derivatives in the food and cosmetic industries may be explained in part by the fact that they are one of a few rare exceptions of naturally derived colors exhibiting comparable stability to artificial dyes. Indeed, processing conditions such as heat or storage under light and oxygen have a minor effect on degradation.


The chemical structure of carminic acid is provided below.




embedded image


Synthesis of Carminic Acid:

Carminic acid is harvested by extraction from the said insect's dried bodies with water or alcohol. During the aqueous based extraction of carminic acid from the insect, an amount of insect protein is also released from the insect and will be contained in the color extract. The level of insect protein is typically less than 0.5%. The aqueous based extract of cochineal is primarily containing carminic acid plus some cochineal protein and other minor extractable substances from the insect. Hereinafter this extract is referred to as cochineal extract solution.


Harvesting and processing of the insects is not an easy task as it determines the final quality of the color. South American countries such as Peru have ideal climatic conditions to grow cactus plants that are the vital food source for these insects, and thus it is here where carmine is industrially most sourced. Crude orange extracts of carminic acid are thus purified prior to being put into color formulation production. In order to obtain 1 kg of extract for colorants, about 100,000 insects need to be processed.


Due to these poor yields and the fact that until a few years ago artificial colors were not an issue for the industry, local economy was more in favor of a profitable business such as vegetables farming (peppers, asparagus, etc.). Nevertheless, due to the recent trend for natural colors in the food industry, the consumption of carmine increased greatly from 2004 to 2010 and shortage provoked high boost in price never before observed. Since it is derived from animal sources, carmine is often at the center of debate with respect to religious discussions where Halal and Kosher preferences both prohibit the use of this color. Thus, alternative methods of synthesis of carminic acid are required.


WO 2006/056585 describes a process in which the aqueous based extraction of carminic acid from the insect, an amount of insect protein is also released from the insect and will be contained in the color extract and it has been reported that the cochineal insect proteins could create some allergy related problems. WO2006/056585 describes a special process to reduce the amount of insect protein from the insect extract solution is described—however, the final produced color composition/product of WO2006/056585 will still comprise some amounts Dactylopius coccus costa insect proteins.


WO 2022/013659 provides a method for the production of carminic acid from insects of the genus Dactylopius coccus. The method comprising: extracting hemocytes from hemolymph of insects, recover the purified hemocytes; culturing the purified hemocytes with culture medium for cultivation of insect cell lines; stimulate and activate insect cell lines; and propagate insect cell lines by producing carminic acid. However, these methods involve the unpredictability and complication of considering bioproduction in the cell lines.


The invention provides methods and compositions for cell-free production of carminic acid. Because the methods of the invention involve cell-free production of carminic acid, the methods provided in the invention related to cell-free production of carminic acid are economic and reliable as compared to other conventional methods of production of carminic acid. In addition, the methods provided in the invention provide higher titer values of the carminic acid from these processes as compared to carminic acid produced from other conventional methods. The methods of the invention are also advantageous because the cell-free production of carminic acid reduces the risk of degradation of carminic acid after production. In addition, the cell-free synthesis method allows for higher concentration of carminic acid being produced without killing the cell. Moreover, cell-free production provides case of purification of carminic acid after the reaction is complete. In certain aspects, the cell-free production of carminic acid allows for the recycling of enzymes used in the reactions for preparation of carminic acid. Thus, the same batch of enzyme may be used for multiple batches of carminic acid being produced. In certain embodiments, the enzymes may be purified by downstream processing by techniques such as filtration and centrifugation.


In one aspect, the invention provides a cell-free production of carminic acid, wherein the method comprises: providing one or more enzymes in a cell-free medium, wherein the one or more enzymes result in transformation of a substrate to carminic acid. In certain embodiments, the substrate that is converted to carminic acid is kermesic acid. In certain embodiments, the enzyme that transforms kermesic acid to carminic acid is C-glucosyltransferase (CGT). The CGT mediated conversion of kermesic acid to carminic acid is provided in FIG. 1. In certain embodiments, the reaction medium for C-glucosyltransferase (CGT) mediated enzymatic transformation of kermesic acid to carminic acid further comprises an activated sugar. In certain embodiments, the activated sugar is UDP-glucose. In certain embodiments, UDP-glucose is an essential co-factor for the transformation of kermesic acid to carminic acid.


In certain aspects, the activated sugar and/or UDP-glucose is added to the reaction medium. In certain embodiments, the activated sugar in the reaction medium for cell-free production of carminic acid is UDP-glucose. In certain embodiments, the UDP-glucose for the reaction medium is generated from sucrose. In certain embodiments, the UDP-glucose is generated in the reaction medium by one or more enzymes. In certain embodiments, the generation of UDP-sugar is mediated by sucrose synthase (SuSy). In certain embodiments, sucrose synthase (SuSy) mediates the conversion of sucrose to UDP-glucose. The SuSy mediated conversion of sucrose to UDP-glucose is schematically described in FIG. 2. As demonstrated in FIG. 2, SuSy is involved in the conversion of sucrose to UDP-glucose, and the produced UDP-glucose is involved in the conversion of kermesic acid to carminic acid. Thus, in certain embodiments, the reaction medium comprises sucrose, which is subsequently converted to UDP-glucose in course of the reaction. In certain embodiments, the conversion of the sucrose to UDP-glucose may be carried out in the same reactor as the conversion of kermesic acid to carminic acid. In other embodiments, the conversion of the sucrose to UDP-glucose may be carried out in a different reactor as the conversion of kermesic acid to carminic acid.


In certain beneficial aspects, the invention provides that the UDP-glucose used in the reaction is generated from other substrates in course of the reaction. In certain embodiments, the UDP moiety in UDP-glucose is recycled in course of the process. The recycling of UDP provides economic efficiency of the processes of the invention. Accordingly, in certain aspects, the production of carminic acid from kermesic acid catalyzed by CGT is conducted in conjunction with other methods for UDP-glucose production or recycling of UDP. In certain embodiments, the overview of the synthetic scheme involving the UDP-glucose production and/or recycling is provided in FIG. 3. In certain embodiments, UDP-glucose is generated by the reaction of uridine triphosphate (UTP) with glucose-1-phosphate. In certain preferred embodiments, the reaction of UTP and glucose-1-phosphate is catalyzed by UTP-glucose-1-phosphate uridylyltransferase (UGP). In certain preferred embodiments, the UGP may be galU.


In certain aspects, glucose-1-phosphate is the source for formation of UDP-glucose. Accordingly, in certain embodiments, glucose-1-phosphate may be added to the reaction for generation of carminic acid. In certain embodiments, the glucose-1-phosphate may be supplied to the reaction for preparation of carminic acid.


In certain embodiments, glucose-1-phosphate is generated during the course of the reaction. In certain embodiments, glucose-1-phosphate is generated enzymatically during the course of the reaction. Accordingly, in certain embodiments, glucose is converted to glucose-6-phosphate by a reaction of ATP (adenosine triphosphate) and glucose. In certain embodiments, reaction between glucose and ATP results in generation of glucose-6-phosphate and adenosine diphosphate (ADP). In certain embodiments, conversion of glucose to glucose-6-phosphate is catalyzed by glucokinase (GLK). In certain embodiments, conversion of glucose to glucose-6-phosphate is catalyzed by hexokinase (HK). In certain embodiments, glucose-6-phosphate is converted to glucose-1-phosphate. In certain embodiments, the conversion of glucose-6-phosphate to glucose-1-phsophate is catalyzed by phosphoglucomutase (PGM).


In certain aspects, the invention further provides that the nucleoside triphosphate species used in the reaction are recycled. In certain embodiments, the recycled nucleoside trisphosphates are ATP and UTP. In certain embodiments, UTP is generated by reaction of UDP and ATP. In certain embodiments, the generation of UTP from UDP and ATP is catalyzed by nucleoside diphosphate kinase (NDK). In certain embodiments, ATP may be generated from ADP and phosphate or polyphosphate. In certain embodiments, the conversion of ADP to ATP is catalyzed by polyphosphate kinase (PPK).


In certain beneficial aspects, the invention provides that the processes of the invention are cost effective because of the recycling of chemical intermediates involved in the reaction. In certain embodiments, the invention provides that chemical intermediates like UDP-glucose, UDP, and glucose-1-phosphate are recycled. Indeed, in certain embodiments, the only reagents required in non-catalytic quantities for the production of carminic acid by conversion of kermesic acid are polyphosphate/phosphate and glucose. Because the processes provided in the invention are conducted in a cell free medium and the ingredients (required in non-catalytic quantities) are economic, the processes of the invention are cost effective.


In certain aspects, the one or more enzymes required for the cell-free production of carminic acid are expressed in a host organism. In certain embodiments, the host organism is selected from a group consisting of: bacteria, yeast, and/or mammalian cells. In certain embodiments, the one or more enzymes are introduced in the host organism by integration into genome of the host organism or on a plasmid. In certain embodiments, the plasmid comprises extrachromosomal DNA, which can be expressed by the host organism. In certain embodiments, host organisms expressing the one or more enzymes are cultured until a pre-determined biomass is achieved to produce the requisite quantity of the one or more enzymes. The predetermined biomass is calculated based on the quantity of the one or more enzymes required for the cell-free production of carminic acid. In certain embodiments, the culture comprising host organisms expressing the one or more enzymes are lysed and used as the reaction medium for the methods provided in the invention. In certain other embodiments, once the culture comprising host organisms is lysed, the cell-debris is removed from the lysed matter to prepare the reaction medium for the methods of the invention. In certain embodiments, the one or more enzymes expressed in the host cells are C-glucosyltransferase (CGT) and/or sucrose synthase (SuSy). In certain embodiments, C-glucosyltransferase (CGT) and/or sucrose synthase (SuSy) are present in the cell-free medium for the cell-free production of carminic acid.


In certain embodiments of the invention, the reaction mixture comprises purified enzymes for the cell-free production of carminic acid. In certain embodiments, the purified enzymes are C-glucosyltransferase (CGT) and/or sucrose synthase (SuSy).


In certain embodiments, the one or more enzymes expressed in host cells are C-glucosyltransferase (CGT), sucrose synthase (SuSy), glucokinase (GLK), hexokinase (HK), phosphoglucomutase (PGM), polyphosphate kinase (PPK), UTP-glucose-1-phosphate uridylyltransferase (UGP), and/or nucleoside diphosphate kinase (NDK). In certain embodiments, C-glucosyltransferase (CGT), sucrose synthase (SuSy), glucokinase (GLK), hexokinase (HK), phosphoglucomutase (PGM), polyphosphate kinase (PPK), UTP-glucose-1-phosphate uridylyltransferase (UGP), and/or nucleoside diphosphate kinase (NDK) are present in the cell-free medium for the cell-free production of carminic acid.


In certain embodiments of the invention, the reaction mixture comprises purified enzymes for the cell-free production of carminic acid. In certain embodiments, the purified enzymes are C-glucosyltransferase (CGT), sucrose synthase (SuSy), glucokinase (GLK), hexokinase (HK), phosphoglucomutase (PGM), polyphosphate kinase (PPK), UTP-glucose-1-phosphate uridylyltransferase (UGP), and/or nucleoside diphosphate kinase (NDK). In certain embodiments, C-glucosyltransferase (CGT), sucrose synthase (SuSy), glucokinase (GLK), hexokinase (HK), phosphoglucomutase (PGM), polyphosphate kinase (PPK), UTP-glucose-1-phosphate uridylyltransferase (UGP), and/or nucleoside diphosphate kinase (NDK). In certain embodiments, the purified enzymes are C-glucosyltransferase (CGT) and/or sucrose synthase (SuSy).


In certain embodiments, the one or more enzymes to produce carminic acid is glucosyltransferase (GT) and/or C-glucosyltransferase (CGT). C-Glycosyltransferases (CGT) catalyze the formation of C-glycosidic bonds for the biosynthesis of C-glycosides. Glycosylation occurs on O-, C-, N-, and S-atoms to produce O-glycosides, C-glycosides, N-glycosides, and S-glycosides, respectively. C-Glycosides are more stable in response to acid hydrolysis and glycosidase than the others. The chemical synthesis of C-glycosides is always challenging due to stereoselectivity and harsh reaction conditions. The difficulty in preparing sugar precursors also restricts the synthesis of C-glycosides. By contrast, the biosynthesis of glycosides involves much milder conditions and has high stereospecificity. Therefore, research on C-glycosyltransferases (CGTs) is beneficial for studying the biosynthesis of C-glycosides, thereby facilitating the development and utilization of C-glycoside-based drugs.


The previously known enzymes for this process for this process of production of carminic acid was from the cochineal beetle Dactylopius coccus (DcUGT) and an engineered variant from the plant Gentiana trifloral (GtCGT). In certain embodiments, the invention provides an improved GT enzyme engineered to change product specificity as a CGT instead of an OGT.


In certain embodiments, the GT and/or CGT used for cell-free production of carminic acid are provided in WO 2022/164226, WO 2022/013659, and/or U.S. Pat. No. 10,724,012, which are incorporated by reference herein in their entirety.


In certain embodiments, GT and/or CGT used for cell-free production of carminic acid is selected from the enzymes having at least 80% amino acid sequence identity from the enzymes provided in Table 1 below. In certain embodiments, GT and/or CGT used for cell-free production of carminic acid is selected from the enzymes having at least 95% amino acid sequence identity from the enzymes provided in Table 1 (reproduced below).












TABLE 1







Accession #
Organism









AXF38108

Bergenia purpurascens




AFJ52990

Linum usitatissimum




KAG8368435

Buddleja alternifolia




AFJ52991

Linum usitatissimum




AUI41123

Rhodiola rosea




KAD6795309

Mikania micrantha




XP_006282251

Capsella rubella




BAF18172

Oryza sativa Japonica Group




A0A0B6VIJ5

Gentiana trifloral




GKV43195.1

Shorea leprosula




CAA7037192.1

Microthlaspi erraticum




CAD6239704.1

Miscanthus lutarioriparius




XP_021750757

Chenopodium quinoa




BAG14302

Gomphrena globose




XP_031382117

Punica granatum











In certain embodiments, the one or more enzymes involved in production of UDP-glucose, which is an ingredient in the cell-free production of carminic acid is sucrose synthase (SuSy). Sucrose synthase (SuSy) converts sucrose and uridine 5′-diphosphate (UDP) into UDP-glucose. Coupling of SuSy and GT reactions in one-pot cascade transformations creates a UDP cycle, which regenerates the UDP-glucose continuously and so makes it an expedient donor for glucoside production. In certain embodiments, SuSy used for production of UDP-glucose is selected from the enzymes having at least 80% amino acid sequence identity from the enzymes provided in Table 2 below. In certain embodiments, SuSy used for production of UDP-glucose is selected from the enzymes having at least 95% amino acid sequence identity from the enzymes provided in Table 2 (reproduced below).












TABLE 2







Accession #
Organism









AXF38108

Bergenia purpurascens




AFJ52990

Linum usitatissimum




KAG8368435

Buddleja alternifolia




AFJ52991

Linum usitatissimum




AUI41123

Rhodiola rosea




KAD6795309

Mikania micrantha




XP_006282251

Capsella rubella




BAF18172

Oryza sativa Japonica Group




A0A0B6VIJ5

Gentiana trifloral




GKV43195.1

Shorea leprosula




CAA7037192.1

Microthlaspi erraticum




CAD6239704.1

Miscanthus lutarioriparius




XP_021750757

Chenopodium quinoa




BAG14302

Gomphrena globose




XP_031382117

Punica granatum











In certain embodiments, the one or more enzymes involved in generation of UDP-glucose and/or recycling of one or more reaction intermediates are provided below. In certain embodiments, the enzymes used for generation of UDP-glucose (by reaction with UTP) and/or recycling of one or more intermediates are selected from the enzymes having at least 95% amino acid sequence identity from the enzymes provided in Table 3 below.












TABLE 3







Enzyme
Accession No.









GLK
AAA27694.1



GLK
WP_331012003.1



PGM
AAC73782.1



PGM
A0AI10EI47



PGM
A0A7M2S2U2



UGP
EEW2752841.1



UGP
WP_021648042.1



UGP
WP_028847555.1



NDK
WP_000963837.1



NDK
CAF21035.1



NDK
WP_066795798



PPK2
WP_010968631



PPK2
WP_160857702










In certain embodiments, the invention provides engineered GT/CGT/SuSy enzymes for the cell-free production of carminic acid. In certain embodiments, the engineered GT/CGT/SuSy enzymes were optimized for cell-free production of carminic acid. In certain embodiments, engineered GT/CGT/SuSy enzymes may include genetic modifications. In certain embodiments, the genetic modifications may be selected from a group consisting of: point mutations, insertions, deletions, and/or any other modifications such that those enzymes result in efficient and optimal cell-free production of carminic acid. In certain embodiments, the GT/CGT/SuSy enzymes used in the cell-free production of carminic acid are any enzymes disclosed in this application.


In certain embodiments, the invention provides engineered and optimized GLK/PGM/UGP/NDK/PPK enzymes for generation of UDP-glucose and/or recycling of reaction intermediates involved in cell-free production of carminic acid. In certain embodiments, the engineered and/or modified GLK/PGM/UGP/NDK/PPK enzymes may include genetic modifications. In certain embodiments, the genetic modifications may be selected from a group consisting of: point mutations, insertions, deletions, and/or any other modifications such that those enzymes result in efficient and optimal cell-free production of carminic acid.


In certain aspects of the invention, the method of the cell-free production does not require the purification of the one or more enzymes from the lysed host organisms. In certain embodiments, the methods of the invention do not require the purification of one or more enzymes from the lysed biomass comprising host cell expressing the one or more enzymes for the cell-free production of carminic acid. In certain embodiments, the methods of the invention do not require the purification of CGT/SuSy/GLK/PGM/UGP/NDK/PPK from the lysed cells for cell-free production of carminic acid. This is advantageous because it increases the efficiency of the method and reduces the costs associated with the purification of these enzymes.


In certain embodiments, the cell-free medium may further comprise any other additional ingredients required for the cell-free production of carminic acid. For example, in certain embodiments, the cell-free medium comprises buffer, kermesic acid, an activated sugar, magnesium chloride, cell lysate, sucrose, and/or water. In certain embodiments, the cell-free reaction mixture further comprises uridine diphosphate (UDP). In certain embodiments, the cell-free reaction mixture further comprises polyphosphate and/or glucose. In certain embodiments, the cell-free reaction mixture comprises UDP-glucose and/or UDP in catalytic quantities. In certain embodiments, UDP-glucose is produced enzymatically in the reaction. In certain embodiments, the reaction mixture comprises glucose-1-phosphate. Glucose-1-phosphate may be generated in the cell-free reaction. Thus, in certain embodiments, glucose-1-phosphate is also present in catalytic quantity. In certain embodiments, the reaction medium comprises glucose and polyphosphate.


In certain preferred embodiments, the processes of the invention utilize kermesic acid, glucose, and polyphosphate as the starting materials for production of carminic acid. In these embodiments, the invention provides that the other intermediates in the process for production of carminic acid may be recycled.


In certain embodiments, the processes of the invention utilize kermesic acid and UDP-glucose as the starting materials for production of carminic acid.


In certain embodiments, the processes of the invention utilize kermesic acid and sucrose as the starting materials for production of carminic acid. In these embodiments, the invention provides that the other intermediates in the process for production of carminic acid may be recycled.


In certain embodiments, the buffer used in the cell-free reaction medium is any buffer suitable for enzymatic conversion of kermesic acid to carminic acid. In certain embodiments, the buffer maintains the pH of about 5 to about 9 in the reaction mixture. In certain embodiments, the buffer maintains the pH of about 6 to about 8 in the reaction mixture. In certain embodiments, the buffer maintains the pH in the range of 6 to 8 in the reaction mixture.


In certain embodiments, the buffer is selected from a group consisting of: Tris, HEPES, phosphate, carbonate/bicarbonate, acetate, sodium hydroxide-glycine, and/or citrate. The concentration of the buffer for the reaction mixture would depend on the concentration of the starting materials and other ingredients in the reaction mixture. In certain embodiments, the buffer is a phosphate buffer. In certain embodiments, the buffer is present at a concentration of about 1 mM to about 250 mM. In certain embodiments, the buffer is present at a concentration of about 5 mM to about 100 mM. In certain embodiments, the phosphate buffer is present at a concentration of about 1 mM to about 250 mM. In certain embodiments, the phosphate buffer is present at a concentration of about 5 mM to about 100 mM.


In certain embodiments, the cell-free reaction medium comprises activated sugar at a concentration of about 0.001 mM to about 50 mM. In certain embodiments, the cell-free reaction medium comprises activated sugar at a concentration of about 0.01 mM to about 5 mM. In certain embodiments, the activated sugar is UDP-glucose.


In certain embodiments, the cell-free reaction medium comprises a source of magnesium ions. In certain embodiments, the source of magnesium ions is magnesium chloride at a concentration of about 0.5 mM to about 40 mM. In certain embodiments, the cell-free reaction medium comprises magnesium chloride at a concentration of about 1 mM to about 20 mM.


In certain embodiments, the cell-free reaction medium further comprises sucrose. In certain embodiments, the sucrose is converted to UDP-glucose. Thus, the concentration of sucrose in the reaction mixture is determined by the quantity of UDP-glucose needed for the reaction for cell-free production of carminic acid. In certain embodiments, sucrose is present at a concentration of about 10 mM to about 1000 mM in the cell-free reaction medium. In certain embodiments, sucrose is present at a concentration of about 20 mM to about 800 mM in the cell-free reaction medium. In certain embodiments, sucrose is present at a concentration of about 50 mM to about 600 mM in the cell-free reaction medium.


In certain embodiments, the cell-free reaction medium further comprises glucose. In certain embodiments, glucose is a starting material to provide UDP-glucose for the conversion of kermesic acid to carminic acid. Thus, the concentration of glucose in the reaction mixture is determined by the quantity of UDP-glucose needed for the reaction for cell-free production of carminic acid. In certain embodiments, glucose is present at a concentration of about 10 mM to about 1000 mM in the cell-free reaction medium. In certain embodiments, glucose is present at a concentration of about 20 mM to about 800 mM in the cell-free reaction medium. In certain embodiments, glucose is present at a concentration of about 50 mM to about 600 mM in the cell-free reaction medium.


In certain embodiments, the cell-free reaction medium further comprises polyphosphate. In certain embodiments, polyphosphate is also a starting material to provide UDP-glucose for the conversion of kermesic acid to carminic acid. Thus, the concentration of polyphosphate in the reaction mixture is determined by the quantity of UDP-glucose needed for the reaction for cell-free production of carminic acid. In certain embodiments, polyphosphate is present at a concentration of about 10 mM to about 1000 mM in the cell-free reaction medium. In certain embodiments, polyphosphate is present at a concentration of about 20 mM to about 800 mM in the cell-free reaction medium. In certain embodiments, polyphosphate is present at a concentration of about 50 mM to about 600 mM in the cell-free reaction medium.


In certain embodiments, the quantity of the one or more enzymes for the cell-free production of carminic acid is dependent on the target quantity of carminic acid to be produced and/or the concentration of other ingredients present in the reaction mixture. In certain embodiments, the one or more enzymes are present in a concentration of from about 1% to about 50% (v/v). In certain embodiments, the one or more enzymes are present in a concentration of from about 2.5% to about 45% (v/v). In certain embodiments, the one or more enzymes are present in a concentration of from about 5% to about 40% (v/v). In certain embodiments, the one or more enzymes are present in a concentration of from about 7.5% to about 30% (v/v).


In certain embodiments, the reaction for production of carminic acid is conducted for a duration till the desired quantity of carminic acid is obtained. In certain embodiments, the reaction for cell-free production of carminic acid is carried out from about 10 minutes to about 48 hours. In certain embodiments, the reaction for cell-free production of carminic acid is carried out from about 10 minutes to about 36 hours. In certain embodiments, the reaction for cell-free production of carminic acid is carried out from about 20 minutes to about 24 hours. In certain embodiments, the reaction for cell-free production of carminic acid is carried out from about 30 minutes to about 20 hours. In certain embodiments, the reaction for cell-free production of carminic acid is carried out from about 1 hour to about 15 hours.


In certain embodiments, the temperature of the reaction mixture for cell-free production of carminic acid is varied to obtain optimal results for the production of carminic acid. In certain embodiments, the temperature of the reaction mixture for cell-free production of carminic acid is from about 15° C. to about 45° C. In certain embodiments, the temperature of the reaction mixture for cell-free production of carminic acid is from about 20° C. to about 40° C. In certain embodiments, the temperature of the reaction mixture for cell-free production of carminic acid is from about 22.5° C. to about 37.5° C. The temperature of the reaction mixture for cell-free production of carminic acid may influence the rate of production of carminic acid. Consequently, the duration of reaction may be adjusted according to the temperature of the reaction mixture to obtain optimal yield of carminic acid in cell-free production of carminic acid.


In certain aspects, the methods provided in the invention may be carried out in any reactor suitable for carrying out the cell-free production of carminic acid. In certain embodiments, the reaction for cell-free production of carminic acid is conducted in a bubble column reactor/bioreactor. In certain embodiments, in the bubble column reactor/bioreactor, the one or more enzymes involved in cell-free production of carminic acid are in a solution. In certain embodiments, the reaction for cell-free production of carminic acid is conducted in a bubble column reactor/bioreactor comprises the lysate from the host organism. In certain embodiments, it is advantageous to use the bubble column reactor/bioreactor for cell-free production of carminic acid when the reaction mixture involves the lysate (or lysate with cellular debris removed) from the host cell organisms in which the one or more enzymes responsible for cell-free production of carminic acid were utilized. In certain embodiments, the reaction for cell-free production of carminic acid is conducted in a packed bed reactor/bioreactor. In certain embodiments, the one or more enzymes are immobilized in the packed bed reactor/bioreactor. The packed bed reactors/bioreactors are preferred for the purified enzymes playing a role in cell-free production of carminic acid. In certain embodiments, the one or more enzymes may be immobilized in a single reactor/bioreactor. In certain other embodiments, the one or more enzymes may be immobilized in different reactors/bioreactors, wherein these reactors/bioreactors are linked sequentially. In certain embodiments, the bioreactor system provided in PCT/US2021/064049, incorporated by reference in its entirety.


The methods provided in the invention are advantageous over other conventional methods of production of carminic acid. In certain embodiments, the methods of the invention provide cell-free production of carminic acid. Because the methods of the invention are conducted in cell-free medium, they provide significant economic efficiency by reducing the cost of production of carminic acid in other conventional methods. In certain embodiments, because the reaction for production of carminic acid is conducted from the lysates from the host organisms expressing the one or more enzymes involved in the reaction, the methods of the invention are cost-efficient. In particular, in certain embodiments, the methods of the invention do not involve the purification of the one or more enzymes. Because purification of individual enzymes is not required in the methods of the invention, provides further economic efficiency by reducing the cost that would have been otherwise required in purifying individual enzymes.


Advantageously, the cell-free production of carminic acid provided herein provides a significantly higher titer value for carminic acid as compared to the conventional methods. The higher titer values of carminic acid provide additional cost advantages for production of carminic acid because the higher titer carminic acid would provide efficiency in purifying and/or concentrating carminic acid from the reaction mixture. In certain embodiments, the methods of the invention provide carminic acid titer value of from at least 5-fold higher than the conventional methods. In certain embodiments, the methods of the invention provide carminic acid titer value of from at least 10-fold higher than the conventional methods. In certain embodiments, the methods of the invention provide carminic acid titer value of from at least 50-fold higher than the conventional methods. In certain embodiments, the methods of the invention provide carminic acid titer value of from at least 100-fold higher than the conventional methods. In certain embodiments, the methods of the invention provide carminic acid titer value of from at least 500-fold higher than the conventional methods. In certain embodiments, the methods of the invention provide carminic acid titer value of from at least 1000-fold higher than the conventional methods. In certain embodiments, the methods of the invention provide carminic acid titer value of from at least 5000-fold higher than the conventional methods.


In some embodiments, the isolated carminic acid has a purity of about 10%, or about 20%, or about 30%, or about 40%, or about 50%, or about 60%, or about 70%, or about 80%, or about 90%, or about 95%, or about 99%, or about 100%.


In other embodiments, the isolated carminic acid has a purity of from about 10% to 95%, or from about 10% to 90%, or from about 10% to 80% or from about 10% to 70%, or from about 10% to 60%, or from about 10% to 50%, or from about 10% to 40%, or from about 20% to 95%, or from about 20% to 90%, or from about 20% to 80% or from about 20% to 70%, or from about 20% to 60%, or from about 20% to 50%, or from about 20% to 40%, or from about 50% to 95%, or from about 50% to 90%, or from about 50% to 80% or from about 50% to 70%, or from about 50% to 60%.


Compositions for Cell-Free Production of Carminic Acid

In certain aspects, the invention provides compositions for cell-free production of carminic acid. The compositions of the invention are utilized for cell-free production of carminic acid in accordance with the methods described above.


In certain embodiments, the compositions of the invention comprise: one or more enzymes in a cell-free medium, wherein the one or more enzymes result in transformation of a substrate to carminic acid. In certain embodiments, the substrate converted to carminic acid is kermesic acid. In certain embodiments, the one or more enzyme is C-glucosyltransferase (CGT). In certain embodiments, the compositions further comprise a cell-free medium. In certain embodiments, the cell-free medium comprises an activated sugar. In certain embodiments, the activated sugar is UDP-glucose. In certain embodiments, the UDP-glucose is added to the cell-free medium.


In certain aspects of the invention, the UDP-glucose in the composition is synthesized in the cell-free medium by the one or more enzymes. In certain embodiments, the UDP-glucose is synthesized from sucrose. In certain embodiments, the one or more enzymes is sucrose synthase (SuSy) that synthesizes UDP-glucose from sucrose. In certain embodiments, the cell-free medium is a cell lysate. In certain embodiments, the cell lysate is a cell lysate from cells from a host organism expressing the one or more enzymes. In certain embodiments, the host organism is selected from a group consisting of: bacteria, yeast, and/or mammalian cells. In certain embodiments, the one or more enzymes are introduced in the host organism by integration into genome of the host organism or on a plasmid. In certain embodiments, the host organisms expressing the one or more enzymes are cultured until a pre-determined biomass is achieved to produce the requisite quantity of the one or more enzymes. In certain embodiments, the composition further comprises cell lysate generated by lysis of cells and subsequent removal of cell debris, for use in the cell-free medium for cell-free production of carminic acid. In certain embodiments, the CGT and SuSy enzymes are present in the cell-free medium for cell-free production of carminic acid. In certain embodiments, the compositions of the invention provide CGT and SuSy that have not been purified or separated.


In certain embodiments, the composition further comprises glucose-1-phosphate. In certain embodiments, glucose-1-phosphate is the source for formation of UDP-glucose. Accordingly, in certain embodiments, glucose-1-phosphate may be added to the reaction for generation of carminic acid. In certain embodiments, glucose-1-phosphate may be supplied to the reaction for preparation of carminic acid.


In certain embodiments, in the compositions of the invention, glucose-1-phosphate is generated during the course of the reaction. In certain embodiments, glucose-1-phosphate is generated enzymatically during the course of the reaction. Accordingly, in certain embodiments, the compositions of the invention comprise glucose and/or ATP. In certain embodiments, glucose is converted to glucose-6-phosphate by a reaction of ATP and glucose. In certain embodiments, reaction between glucose and ATP results in generation of glucose-6-phosphate and adenosine diphosphate (ADP). In certain embodiments, conversion of glucose to glucose-6-phosphate is catalyzed by glucokinase (GLK). In certain embodiments, conversion of glucose to glucose-6-phosphate is catalyzed by hexokinase (HK). In certain embodiments, glucose-6-phosphate is converted to glucose-1-phosphate. In certain embodiments, the conversion of glucose-6-phosphate to glucose-1-phsophate is catalyzed by phosphoglucomutase (PGM). Accordingly, in certain embodiments, the composition comprises GLK, HK, and/or PGM.


In certain aspects, the invention further provides that the nucleoside triphosphate species used in the reaction are recycled. In certain embodiments, the recycled nucleoside trisphosphates are ATP and UTP. In certain embodiments, UTP is generated by reaction of UDP and ATP. In certain embodiments, the generation of UTP from UDP and ATP is catalyzed by nucleoside diphosphate kinase (NDK). In certain embodiments, ATP may be generated from ADP and phosphate or polyphosphate. In certain embodiments, the conversion of ADP to ATP is catalyzed by polyphosphate kinase (PPK). In certain embodiments, the compositions of the invention further comprise ATP, UTP, and/or UDP. In certain embodiments, the compositions of the invention further comprise PPK.


In certain embodiments, the composition further comprises C-glucosyltransferase (CGT), sucrose synthase (SuSy), glucokinase (GLK), hexokinase (HK), phosphoglucomutase (PGM), polyphosphate kinase (PPK), UTP-glucose-1-phosphate uridylyltransferase (UGP), and/or nucleoside diphosphate kinase (NDK). In certain embodiments, C-glucosyltransferase (CGT), sucrose synthase (SuSy), glucokinase (GLK), hexokinase (HK), phosphoglucomutase (PGM), polyphosphate kinase (PPK), UTP-glucose-1-phosphate uridylyltransferase (UGP), and/or nucleoside diphosphate kinase (NDK) are present in the cell-free medium for the cell-free production of carminic acid.


In certain embodiments, the cell-free medium may further comprise any other additional ingredients required for the cell-free production of carminic acid. For example, in certain embodiments, the cell-free medium comprises buffer, kermesic acid, an activated sugar, magnesium chloride, cell lysate, sucrose, and/or water. In certain embodiments, the buffer used in the cell-free reaction medium is any buffer suitable for enzymatic conversion of kermesic acid to carminic acid. In certain embodiments, the buffer maintains the pH of about 5 to about 9 in the reaction mixture. In certain embodiments, the buffer maintains the pH of about 6 to about 8 in the reaction mixture. In certain embodiments, the buffer maintains the pH in the range of 6 to 8 in the reaction mixture. In certain embodiments, the buffer is a phosphate buffer. In certain embodiments, the buffer is present at a concentration of about 1 mM to about 200 mM. In certain embodiments, the buffer is present at a concentration of about 5 mM to about 100 mM.


In certain embodiments, the cell-free reaction medium comprises activated sugar at a concentration of about 0.001 mM to about 50 mM. In certain embodiments, the cell-free reaction medium comprises activated sugar at a concentration of about 0.01 mM to about 5 mM. In certain embodiments, the activated sugar is UDP-glucose.


In certain embodiments, the cell-free reaction medium comprises magnesium chloride at a concentration of about 0.5 mM to about 40 mM. In certain embodiments, the cell-free reaction medium comprises magnesium chloride at a concentration of about 1 mM to about 20 mM.


In certain embodiments, the cell-free reaction medium further comprises sucrose. In certain embodiments, the sucrose is converted to UDP-glucose. Thus, the concentration of sucrose in the reaction mixture is determined by the quantity of UDP-glucose needed for the reaction for cell-free production of carminic acid. In certain embodiments, sucrose is present at a concentration of about 10 mM to about 1000 mM in the cell-free reaction medium. In certain embodiments, sucrose is present at a concentration of about 20 mM to about 800 mM in the cell-free reaction medium. In certain embodiments, sucrose is present at a concentration of about 50 mM to about 600 mM in the cell-free reaction medium.


In certain embodiments, the cell-free reaction medium further comprises glucose. In certain embodiments, the concentration of glucose in the reaction mixture is determined by the quantity of UDP-glucose needed for the reaction for cell-free production of carminic acid. In certain embodiments, glucose is present at a concentration of about 1 mM to about 1000 mM in the cell-free reaction medium. In certain embodiments, glucose is present at a concentration of about 10 mM to about 1000 mM in the cell-free reaction medium. In certain embodiments, glucose is present at a concentration of about 50 mM to about 600 mM in the cell-free reaction medium.


In certain embodiments, the cell-free reaction medium further comprises phosphate/polyphosphate. In certain embodiments, the cell-free reaction medium further comprises polyphosphate. In certain embodiments, the concentration of polyphosphate in the reaction mixture is determined by the quantity of UDP-glucose needed for the reaction for cell-free production of carminic acid. In certain embodiments, polyphosphate is present at a concentration of about 0.1 g/L to about 500 g/L in the cell-free reaction medium. In certain embodiments, polyphosphate is present at a concentration of about 1 g/L to about 100 g/L in the cell-free reaction medium. In certain embodiments, polyphosphate is present at a concentration of about 1 g/L to about 60 g/L in the cell-free reaction medium. In certain embodiments, polyphosphate is present at a concentration of about 5 g/L to about 40 g/L in the cell-free reaction medium. In certain embodiments, polyphosphate is present at a concentration of about 25 g/L.


In certain embodiments, the cell-free reaction medium further comprises UTP and/or UDP. In certain embodiments, the concentration of UTP and/or UDP in the reaction mixture is determined by the quantity of UDP-glucose needed for the reaction for cell-free production of carminic acid. In certain embodiments, UTP and/or UDP is in the concentration of about 0.01 M to about 100 μM in the cell-free medium. In certain embodiments, UTP and/or UDP is in the concentration of about 0.1 μM to about 50 M in the cell-free medium. In certain embodiments, UTP and/or UDP is in the concentration of about 0.1 μM to about 10 UM in the cell-free medium. In certain embodiments, UTP and/or UDP is in the concentration of about 1 μM in the cell-free medium. In certain embodiments, UTP and/or UDP is in the concentration of about 5 μM in the cell-free medium.


In certain embodiments, the cell-free reaction medium further comprises ATP. In certain embodiments, the concentration of ATP in the reaction mixture is determined by the quantity of UDP-glucose needed for the reaction for cell-free production of carminic acid. In certain embodiments, ATP is in the concentration of about 0.01 μM to about 100 μM in the cell-free medium. In certain embodiments, ATP is in the concentration of about 0.1 μM to about 50 μM in the cell-free medium. In certain embodiments, ATP is in the concentration of about 0.1 μM to about 10 μM in the cell-free medium. In certain embodiments, ATP is in the concentration of about 1 μM in the cell-free medium. In certain embodiments, ATP is in the concentration of about 5 μM in the cell-free medium.


In certain embodiments, the cell-free reaction medium comprises glucose-6-phosphate and/or glucose-1-phosphate. In certain embodiments, glucose-6-phosphate and/or glucose-1-phosphate are generated and/or recycled in the reaction medium. Thus, in certain embodiments, glucose-6-phosphate and/or glucose-1-phosphate are present in catalytic quantities in the reaction medium. In certain embodiments, glucose-6-phosphate and/or glucose-1-phosphate may be added in the reaction medium. In certain embodiments, glucose-6-phosphate and/or glucose-1-phosphate are present at a concentration of from about 0.01 mM to about 500 mM. In certain embodiments, glucose-6-phosphate and/or glucose-1-phosphate are present at a concentration of from about 0.01 mM to about 1 mM. In certain embodiments, glucose-6-phosphate and/or glucose-1-phosphate are present at a concentration of from about 1 mM to about 500 mM. In certain embodiments, glucose-6-phosphate and/or glucose-1-phosphate are present at a concentration of from about 10 mM to about 500 mM. In certain embodiments, glucose-6-phosphate and/or glucose-1-phosphate are present at a concentration of from about 10 mM to about 100 mM.


In certain embodiments, the quantity of the one or more enzymes for the cell-free production of carminic acid is dependent on the target quantity of carminic acid to be produced and/or the concentration of other ingredients present in the reaction mixture. In certain embodiments, the one or more enzymes are present in a concentration of from about 1% to about 50% (v/v). In certain embodiments, the one or more enzymes are present in a concentration of from about 2.5% to about 45% (v/v). In certain embodiments, the one or more enzymes are present in a concentration of from about 5% to about 40% (v/v). In certain embodiments, the one or more enzymes are present in a concentration of from about 7.5% to about 30% (v/v).


In certain aspects of the invention, the compositions of the invention are in a bubble column reactor, wherein the one or more enzymes are in a solution. In certain embodiments, the compositions of the invention are in a packed bed reactor, wherein the one or more enzymes are immobilized.


In some embodiments, the enzymes may be immobilized. In some embodiments, immobilized enzymes may be immobilized onto solid supports. Non-limiting examples of solid supports may include (but are not limited to) epoxy methacrylate, carboxymethyl-cellulose, starch, collagen, ion exchange resins, amino C6 methacrylate, or microporous polymethacrylate. In further embodiments, various surface chemistries may be used for linking the immobilized enzyme to a solid surface, including but not limited to covalent, adsorption, ionic, affinity, encapsulation, or entrapment. In other embodiments, immobilized enzymes may be immobilized in crosslinked enzyme aggregates. In other embodiments, the enzymes are non-immobilized. Either immobilized or non-immobilized enzymes may be employed in batch or continuous synthesis. For example, an immobilized enzyme on a solid support may be used in a cartridge through which a reaction mixture passes, whereby an immobilized enzyme may catalyze modification of substrate to produce the product at a high titer. Alternatively, a continuous method may comprise micro mixing of enzyme solution and substrate to produce the product at a high titer, while continuously removing product, removing (e.g., recovering) substrate, or both. In some embodiments removed (e.g., recovered) substrate may be recycled to increase process efficiency and overall yield.


In some embodiments, C-glucosyltransferase (CGT), sucrose synthase (SuSy), glucokinase (GLK), hexokinase (HK), phosphoglucomutase (PGM), polyphosphate kinase (PPK), UTP-glucose-1-phosphate uridylyltransferase (UGP), and/or nucleoside diphosphate kinase (NDK) are immobilized.


In some embodiments, C-glucosyltransferase (CGT), sucrose synthase (SuSy), glucokinase (GLK), hexokinase (HK), phosphoglucomutase (PGM), polyphosphate kinase (PPK), UTP-glucose-1-phosphate uridylyltransferase (UGP), and/or nucleoside diphosphate kinase (NDK) are non-immobilized.


In some embodiments, enzymes are recycled by ultrafiltration. In some embodiments ion exchange resins may be used to capture carminic acid during production. For example, amine-functionalized solid support may be added to capture carminic acid for continuous purification from reaction mixture. In certain embodiments, the bioreactor system provided in PCT/US2021/064049, incorporated by reference in its entirety.


Advantageously, the cell-free production of carminic acid provided herein provides a significantly higher titer value for carminic acid as compared to the conventional methods. The higher titer values of carminic acid provide additional cost advantages for production of carminic acid because the higher titer carminic acid would provide efficiency in purifying and/or concentrating carminic acid from the reaction mixture. In certain embodiments, the methods of the invention provide carminic acid titer value of from at least 5-fold higher than the conventional methods. In certain embodiments, the methods of the invention provide carminic acid titer value of from at least 10-fold higher than the conventional methods. In certain embodiments, the methods of the invention provide carminic acid titer value of from at least 50-fold higher than the conventional methods. In certain embodiments, the methods of the invention provide carminic acid titer value of from at least 100-fold higher than the conventional methods. In certain embodiments, the methods of the invention provide carminic acid titer value of from at least 500-fold higher than the conventional methods. In certain embodiments, the methods of the invention provide carminic acid titer value of from at least 1000-fold higher than the conventional methods.


In some embodiments, the isolated carminic acid has a purity of about 10%, or about 20%, or about 30%, or about 40%, or about 50%, or about 60%, or about 70%, or about 80%, or about 90%, or about 95%, or about 99%, or about 100%.


In other embodiments, the isolated carminic acid has a purity of from about 10% to 95%, or from about 10% to 90%, or from about 10% to 80% or from about 10% to 70%, or from about 10% to 60%, or from about 10% to 50%, or from about 10% to 40%, or from about 20% to 95%, or from about 20% to 90%, or from about 20% to 80% or from about 20% to 70%, or from about 20% to 60%, or from about 20% to 50%, or from about 20% to 40%, or from about 50% to 95%, or from about 50% to 90%, or from about 50% to 80% or from about 50% to 70%, or from about 50% to 60%.


VII. EXAMPLES
Example 1: Bioproduction of Carminic Acid

The reaction conditions for the reactions are provided in Table 4 below. The exemplary reaction conditions provided below are for the reactions provided for the conversion of kermesic acid to carminic acid and/or conversion of sucrose to UDP-glucose.









TABLE 4







Reaction conditions:










Component
Working Range







Buffer
pH 6-8, 5-100 mM











UDP-glucose
0.01-5
mM



Magnesium chloride
1-20
mM



Kermesic acid
0.1-50
g/L



Sucrose
50-600
mM










Host microbe lysate
5-40% (v/v)











with enzymes












Time
0.5 h-48 h 



Temperature
20° C.-40° C.











FIG. 4 provides the results from the reaction. As demonstrated in FIG. 4, upon addition of CGT to a mixture comprising kermesic acid, the kermesic acid is converted to carminic acid.


Example 2: Reaction for Generation of UDP-Glucose and/or Recycling of Intermediates

The reaction conditions for the reactions for generation of UDP-glucose and/or recycling of intermediates are provided in Table 5 below.









TABLE 5







Reaction conditions










Component
Working Range







Buffer
pH 6-8, 5-200 mM











Magnesium chloride
1-100
mM



Kermesic acid
0.1-50
g/L



Polyphosphate
1-60
g/L



UTP or UDP
0.1-10
μM



ATP
0.1-10
μM



Glucose, glucose-1-phosphate,
0.01-500
mM



glucose-6-phosphate, or UDP-



glucose










Host microbe lysate(s) with
0.5-40% (v/v)











enzymes












Time
0.5 h-48 h 



Temperature
20° C.-40° C.










In certain embodiments, the enzymes in the aforementioned Table 5 are CGT, SuSy, NDK, UGP, PPK, PGM, GLK and/or HK.


Table 6 provides exemplary sequences for glycosyltransferase enzymes in accordance with the methods of invention.









TABLE 6







Glycosyltransferase Enzymes










SEQ





ID
Accession #
Organism
Sequence













1
AXF38108

Bergenia

MGSEPLVHVFLVSFPGQGHVNPLLRLGKRLAS





purpurascens

KGLLVTFSTPDSIGKQMRKASNLTDQPTPVGSG





YIRFEFFEDGWAEDEPMRQDLDLYLPQLELVG





KKLIPEMLKKHAEQDRPVSCLINNPFIPWVSDV





ADELGIPSAMLWVQSTACFSAYYHYYHGIVPF





PSETDPEIDVQLPHIPLLKYDEVPSFLHPTTPYPF





LRRAILGQYKNLHKPFCILMETFYELEPEVIDY





MSKLCPIKPVGPLFKNPTAPGTTVRGDFMTAD





DCIEWLDSKPASSVVYISFGSVVYLKQEQIDEIA





YGLLNAGISFLWVMKPPHKDAGLELLVLPDGF





LEKAGDKGKMVQWSPQEQVLAHPSVACFVTH





CGWNSTMESLTSGMPVVAFPQWGDQVTDAVY





LCDVFKTGVRMCRGEAENRVIPRDEVEKCLLE





AISGPKAEEMKKNALKWKELAEAAVAEGGSS





DRNLQEFVDEVRRRSVGLTYKSTAGKIVEVVD





SALPALAGQV





2
AFJ52990

Linum

MGSSSSEKVLHVLLVCFPGQGHINPFLRLANLL





usitatissimum

ASHGLLVTFCINKTTGLKMKMSDNKSAVQFDF





FDEGLDEEQIKVIPLDQLMNRLEETGRKALPEII





EKHSENGQPVSCLVSNPFLPWVSDVAVSLDIPS





AILWMQSCACESSYYHYHNKLARFPTENEPEC





DVVLPSMPVLKHDEVPSFLHPSTPHPFLATAIL





GQIAFLGKVFCILMETFQELEPEIIRHVSTLQNNI





KPVGPLCLTGKISGGDLMEVDDDCIKWLDGKD





ESSVVYISMGSIVSMDPTQREEFAYGLINSGLPF





LWVVRPGHGESDGPGHQIIFPSVLEEKGKMVR





WAPQEEVLRHPAVACFVTHCGWNSTMEAISA





GKPVVTFPQWGDQVTDAKFLVDVFEVGVRMG





RGATTTKMVKREEVERCVVEATVGEKAEMLR





RNAARWKKEAEAAVAEDGSSTRSLLEFVEEVK





KRNGTTS





3
KAG8368435

Buddleja

MGSSVDHFDEGPLQNIHVFMVSFPGQGHVNPL





alternifolia

LRLGKRLASSGLFVTFSAPEFAGRSIRKSNKITE





DEATPLGRGMIRFEFFDDGWALDHPGRDNLD





MYLAQLERVGRETLPMMIRKQGEAGRPVSCLI





NNPFIPWVSDVAEYLGMPSAVLWIQSCACFSA





YYHFYHNLVPFPTENEPEIEVELPFMPSLKHDEI





PSFLHPSTPYPFLGRAILGQFKNLHKPFCILMDT





FQELENEIIEYTSKLIGRPIKTIGPLFKNSDDNSK





SSDIRADFFAADDCIEWLDSKPERSVVYISFGSV





VHLKQEQIDEIAYGLLNAGVSFLWVLRPPPKEH





MNWVPHVLPEGFLGEAGDKGRIVGWAPQEAV





LAHPSTACFVTHCGWNSTVEALTSGVPVVAFP





QWGDQVTDAKFLVDVFRVGVRMCRGEAEDR





VVGRDEVAMCLKAAVEGPEAAKMKENALKW





KNAAAAAVAAGGSSYMNMQDFVEEVVRKSQ





QKKM





4
AFJ52991

Linum

MGSSSSEKALHVLLVCFPGQGHINPFLRLANLL





usitatissimum

ASHGLLVTFCINKTTGGQMKIPKNNLPSDNKPT





IQFDFFDEGLDDEQIKVTPLDQLMTRLEETGRK





ALPGIIEKYSENGQPVSCLVSNPFLPWVCDVAV





SLDIPSAILWMQSCACFSSYYHYHNKLARFPTE





NDAECDVVLPSMPVLKHDEVPSFLHPSTPYPFL





ATAILGQFAYLDKVFCILMETFQELEPEIIRHVS





TLHNNIKPVGPLCLTGKISGGDLMEVNDDCIK





WLDGKDKSSVVYISMGSVVSMDPTQREEFAY





GLMNSGLPFLWVVRPGYGEGDEPDHQIIFPSGL





EGRGKMVRWAPQEEVLRHPAVACFVTHCGW





NSTMEAISAGKPVVTFPQWGDQVTDAKFLVDV





FEVGVRMGRGATTTKLVKRDEVERCVVEATV





GEKAEVLRRNAMRWMKEAEAAVAEDGSSTRS





LLEFVEEVKKRNGATL





5
AUI41123

Rhodiola rosea

MGSEPLVHVFLVSFPGQGHVNPLLRLGKRLAS





KGLLVTFTTPESIGHQMRKANKIVDGQPNPVG





DGFLRFEFFEDGWDEHEVKRQDLDLYLPQLEL





VGKVVIPQMIKRNAEAGRPVSCLINNPFIPWVS





DVAESLGLPSAMLWVQSAACFSAYYHYSKNL





VPFPSETDPEIDVQLPNMPLLKYDEVPSFLHPTT





PYPFLRRAIMGQYNNLEKPFCVLMDTFDELEH





DVIEFMSKFVPIRPVGPLFKNPKAPAAVRGDFM





QADDCIGWLDAKPPGSVVYISFGSVVYLQQEQ





VDEIAQGLLSSKVGFLWVMKPPHPDAGLELLK





LPEGFLEEAGDRGKVVQWSPQEQVLAHPSVAA





FVTHCGWNSTMEALTSGMPVIAFPQWGDQVT





DAKYLVDEFKVGVRMCRGEAENRVVSREEVR





KCLEEATVGEKAAEMKANAAKWKKAATEAFT





EGGSSDRNLQAFVDDVRRKSLEIGKKSTKLGL





DIDIPVAKDAISA





6
KAD6795309

Mikania

METKHDLVHVFLVTFPAQGHVNPLLRLGKLIA





micrantha

SKGNVLVTFSATKSIGKRMKNAGAPVSGEPVP





VGNRGGMLRFEFFDDGCSEHNDDERNDFVAY





LPKLEAYGKTALTEIISHHAENGQPVSCLINNPF





VPWVSDLAKDLNIPCAMLWVQSCSCFSAYYH





YQNSLVTFPSEEQPDIDVQLPNMPVLKSDEIPSF





LHPSTPYPFLRRAILGQFKNLSNNFCVLMETFEE





LEGDLIKYMSQICQIRAVGPLFKNPMLDNSISG





DLIKADDCLEWLDSKQPSSVVYISFGSIVSLNEE





QVGEMAYGVLNSGVSFLWVMRTDAISTGEPG





RLPVGFMEEAGERGMVVQWSPQAQVLAHPAV





SCFVTHCGWNSTMEALSSGVPVVAFPQWGDQ





VTDAKYLVDEWKVGIRMCRGEAEHRVIGRTE





VEACIREATGGVNQAEMKMNAMKWKKAAEA





AVAEGGSSDRNIQNFVDEIRNISFTKP





7
XP_006282251

Capsella

MGFGSSSPSKPIHVMMVSFMGQGSVTPLFRLG





rubella

KLIASKGTVVTFVSPEFWAKKMREANKIVDSE





LKPVGAGAIRFESYDKEWTEEDDSRGDFSAYM





SHLEDAGKREVSKLVTSYMEKKDHVACLINNT





FLPWVGDVAEEFNIPCALLWVQSAACFSAYYH





YQDGSVPFPTETEPERDVKLPCFPVLKHDEIPNF





LHPSSKYPGFSKAILGQFKNLRRPLCILMNSFNA





LEQELIEYMSAFCQIKTVGPLSLFAKEVSSDVSA





DMCKASDECIEWLDSRPKSSVVYISFGTVVYFK





QEQMEEVIYGVLNSGLSFLWVIRPPVKAMRVE





ANVLPQELFDAANSGRGKIVEWSPQEKVLAHP





SVSCFVSHCGWNSTTEALSIGVPVVCLPKLGDQ





VMNAVCLIDIFKMGVRLGRGAIVDRVAPRKEV





TEKLLEAAVGEKAEELKKNALKWKAKAEAAV





APGGSSDKSLWEFLEMIGVRVSQEKPNIHA





8
BAF18172

Oryza sativa

TCGVSNTTNATTLVGFRGKHTTRAGGNKALRS





Japonica

MEPHVLLVSFPMQGHVNPLLRLGRRLAATGLL




Group
VTFTTVRLAAGGGRLRDVPEDGACADVGLGR





LRFEYLRDDDDDGDERCQQLAPNDVLSHVTA





VGPSALAEFIDGQADAGRPVTFVVNNIFVPWA





LDVAAGMGIPCAMLWIQPCSVLSIYYHFYESPE





AFPTAADPDVPVELPGLPVMAMVELPFMVRPE





YAQCLWGDTLRAQVGAIKRTVSWVLVNSFYE





LERSAVDALRAHTTVKLAPIGPLLEHGHDNGG





GDDGAPAPALGAEDNDRCVAWLDAQPPRSVV





YVAFGSLVNIGRDETAAVAEGLVATGRPFLWV





VRDDSRDLVPEAVLAACRGDKAGKITAWCPQ





GRVLAHGAVGCFVTHCGWNSIMEALAAGVPV





VGYPWWSDQFANAKFLVEDYKVGVRLPAPVT





GGELRACVDRVMSGPEAAVIRKRAMHWKREA





AAAVADGGSSDRSLQDFVDHVRRSKGPEELAR





LAQDIQIMNGPVNPVLV





9
A0A0B6VIJ5

Gentiana

MGSLTNNDNLHIFLVCFIGQGVVNPMLRLGKA





trifloral

FASKGLLVTLSAPEIVGTEIRKANNLNDDQPIK





VGSGMIRFEFFDDGWESVNGSKPFDVWVYINH





LDQTGRQKLPIMLKKHEETGTPVSCLILNPLVP





WVADVADSLQIPCATLWVQSCASFSAYYHYH





HGLVPFPTESEPEIDVQLPGMPLLKYDEVPDYL





HPRTPYPFFGTNILGQFKNLSKNFCILMDTFYEL





EHEIIDNMCKLCPIKPIGPLFKIPKDPSSNGITGN





FMKVDDCKEWLDSRPTSTVVYVSVGSVVYLK





QEQVTEMAYGILNSEVSFLWVLRPPSKRIGTEP





HVLPEEFWEKAGDRGKVVQWSPQEQVLAHPA





TVGFLTHCGWNSTQEAISSGVPVITFPQFGDQV





TNAKFLVEEFKVGVRLGRGELENRIITRDEVER





ALREITSGPKAEEVKENALKWKKKAEETVAKG





GYSERNLVGFIEEVARKTGTK





10
GKV43195.1

Shorea

MGSESLVHVLLVSFPGQGHVNPLLRLGKRLAS





leprosula

KGLLVTFTTPETTGKQMRKASNVSEEPTAVGD





GYIRFEFFEDGWDEDEPRRQDLDQYLPQLEKV





GKIVIPEMIKRNAEQNRPVSCLINNPFIPWVSVV





AESLGLPSAMLWVQSCACFAAYYHYHHGLVS





FPSETDPEIDVQLPSMPLLKYDEVPSFLHPTTPY





PFLRRAILGQYKSLDKPFCILMESFQELEPEIIEY





MSKLCPIKPVGPLFKNPKAPNSAVRGDLMPQA





DDCIDWLNTKPPSSVVYISFGSVVYLKQEQVDE





IAHALLNSGITFLWVMKPPHKDSGYELLTLPEG





FLEKVGNNGQVVQWSPQEKVLAHPAVACFVT





HCGWNSTMESLSSGMPVVAFPQWGDQVTDAV





YLTEVFKTGVRMCRGEAEDRIIARDEVEKCLK





EAMVGPKAMEMKQNALKWKAAAEAAIAEGG





SSDRNLQAFVDEVKRRSMEIAAGKSTKGVGGD





LTKKSTENGKVEVEA





11
CAA7037192.1

Microthlaspi

MDQNSFPLPPHVMLVSFPGQGHVNPLLRLGKL





erraticum

LASKGLLVTFVTTESWGKKMRTANNIQDRVLK





PIGKGYIRFDFFDDGLPEDDDASRTDFTILRPQL





ELVGQREIKSLVRRYEEVTKQPVTCLINNPFVS





WVCDVAEDLQIPCAVLWVQSCACLASYYYYH





HKLVDFPTKTDPKIDVQIPGMPLLKHDEIPSFIH





PSSPYSALREVIIDQIKRLHKPFAVLIDTIHSLEQ





DIIDHMSDVRLPGVIRPIGPLYKMAKTLASDEIN





GDMSESTDHCMEWLDSQPVSSVVYISFGTVAY





LKQEQINEIAYGVLNAGVSFLWVIRTQELGVN





KERHVLPEEVKGKGKIVEWCSQEKVLAHPSIV





CFVTHCGWNSTMEAVSSGVPTVCCPQWGDQV





TDAVYMIDVLKTGVRLCRGETEERVVPREEVA





ERLREITKGEKATELKKNALKWKEEAEAAVAR





GGSSDRNIEEFVEKLGAKRVGKQNGGLEKONG





GLAKONGSLNHVLS





12
CAD6239704.1

Miscanthus

MSAREETAPAAAAAAPPHVVLVCFPSQGNLNP





lutarioriparius

TLRLAKRLAAKGLLVTCCTTSSIGACLAAASSS





GVVSTGGDGVRVGSGRIRFEFLDDHGNEKDDL





MRYFETSAPAAFVELLGRQAEAGRPVTYVVGN





PFLPWVVDVAAEAGVPAAVLWVQSCAVLSLY





YHYARGLVEFPPEDDIDARVALPGLPPLSVADV





PSFLLPSNPYKMIADAIQGQFRNVDKAAWVFV





NSFTELERDVLAALPGVTPRPPQLIPVGPLIELE





EDGAAVRGDLIKAADDDCVGWLDAQPPRSVV





YASVGSVVVLSAEEVAEMAHGLASTGRPFLW





VVRPDTRPLLPEGFLDTVAGCGMVVPWSPQER





VLEHAATACFLTHCGWNSTLETVAAGVPVVAF





PQWGDOCTDAKFLVDELRMGVRLRAPLRREA





VREAVDAAVAGPEADAMLSRARSWSAVARGA





VAPGGSSDRHVQAFVDEVVQRACGRQPDEVT





MMSG





13
XP_021750757

Chenopodium

MGSETQIIHNNELDQLVHVFMISFPGQGHINPLL





quinoa

RLGKRIASKGFLVTFTTTENLGQGIRGSNDAVS





DQPVPIGDGFIRFEFFDDEWPDGDPKKFDMDQ





YLPQLEDVGRRWVPERLAVLAQEGRPVSCLIN





NPFIPWVSDVAEELGLPSAMLWPQSCACFLAY





YYFHHNMIPFPTEDALEIDVEVPTLPLLKWDEIP





TFLHPTTPYAFLKRAILAQYKNLSKPFCILMDTF





YELERSTVDHTIELLAPTPIRTIGPLFKKPIPGGA





RVRADPLRPNQDCLKWLDGKPDGSVVYISFGT





IVFPPQKQIDEIAAGIEAAGITFLWVMKPPAKEA





KMSPHTLPDGFLDRIGDNGKVVQFAPQEQVLA





HPAVSCFVTHCGWNSTMESLSYGVPMVAFPS





WGDQVTDAKFICDVFKTGIQLTRGEHEKRLITK





EEVEKCLRDATSGPKAVEMKKIALKWKDLAD





EAIADGGSSDKNFDFFIDQVRKRGEIVVANAKK





VANGLPTKENGH





14
BAG14302

Gomphrena

MGSETHHSNDPQLTHIFMISFPGQGHINPLLRLG





globose

KRVASKGLLVTFATTENFGQYIRISNDAISDQP





VPVGDGFIRLEFFDDEWPDGDPRKHDMDQYLP





QLEKVGRKWVTQRLAALAHEYRPVSCLVNNP





FLPWVSDLAEELGLCSAMLWPQSCACFLAYYY





FHNNLVPFPSQDALEIDVEIPTLPLLKWDEIPTF





LHPTTPYAFLKRAILAQYNNLTKPFCVLMDTFY





ELEKPTVDHTIELLAPLPIKPVGPLFKKKVTGGS





DVRADPIRPDQDCLSWLDGQPDGSVIYISFGTV





VFLPQKQVDEIAAALEAADLSFLWVMKPPLKE





SGWTPHCLPDGFLERVGQNGKVVQFAPQEQVL





AHPALACFMTHCGWNSTMESLTSGVPVIAFPS





WGDQVTDAKFLCDVYKTGIQLTRGEHEKKIIP





RDEVEKCLREATSGPKAEEMKENALKWKAHA





EETIADGGSSDQNIDFFVEGVRKRSEVVLAKAT





NGVDANGYSLHIEANG





15
XP_031382117

Punica

MGSESSLVHVFLVSFPGQGHVNPLLRLGKRLA





granatum

SKGLLVTFTTPESIGKQMRKASNISDQPAPVGD





GFIRFEFFEDGWDEDEPRRQDLDQYLPQLEKV





GKVLIPQMIQKNAEQGRPVSCLINNPFIPWVSD





VAETLGLPSAMLWVQSCACFLAYYHYYHGLV





PFPSENAMEIDVQLPSMPLLKHDEVPSFLYPTTP





YPFLRRAILGQYKNLEKPFCILMDTFQELEHEII





EYTSKICPIKTVGPLFKNPKAPNTTVKGDFMKA





DDCIGWLDSKPASSVVYVSFGSVVYLKQDQW





DEIAYGLLNSGVNFLWVMKPPHKDSGYTVLTL





PEGFLEKAGDRGKVVQWSPQEQVLAHPATACF





VTHCGWNSSMEALTSGMPVVAFPQWGDQVTD





AKYLVDEFKVGVRMCRGEAEDKLITRDVVEQ





CLREATQGPKAAEMKKNALKWKAAAEASFVE





GGSSDRNLQAFVDEVKRRSIEITASKPAVKAAP





NGVVAAAESVVETKANGKVELAA









Table 7 provides exemplary sequences for sucrose synthase enzymes in accordance with the methods of invention.









TABLE 7







Sucrose Synthase Enzymes










SEQ





ID
Accession #
Organism
Sequence





16
WP_004872341.1

Acidithiobacillus

MIEALRQQLLDDPRSWYAFLRHLVASQRDS





caldus

WLYTDLQRACADFREQLPEGYAEGIGPLEDF





VAHTQEVIFRDPWMVFAWRPRPGRWIYVRIH





REQLALEELSTDAYLQAKEGIVGLGAEGEAV





LTVDFRDFRPVSRRLRDESTIGDGLTHLNRRL





AGRIFSDLAAGRSQILEFLSLHRLDGQNLMLS





NGNTDFDSLRQTVQYLGTLPRETPWAEIRED





MRRRGFAPGWGNTAGRVRETMRLLMDLLDS





PSPAALESFLDRIPMISRILIVSIHGWFAQDKVL





GRPDTGGQVVYILDQARALEREMRNRLRQQ





GVDVEPRILIATRLIPESDGTTCDQRLEPVVGA





ENVQILRVPFRYPDGRIHPHWISRFKIWPWLE





RYAQDLEREVLAELGSRPDLIIGNYSDGNLVA





TLLSERLGVTQCNIAHALEKSKYLYSDLHWR





DHEQDHHFACQFTADLIAMNAADIIVTSTYQ





EIAGNDREIGQYEGHQDYTLPGLYRVENGID





VFDSKFNIVSPGADPRFYFSYARTEERPSFLEP





EIESLLFGREPGADRRGVLEDRQKPLLLSMAR





MDRIKNLSGLAELYGRSSRLRGLANLVIIGGH





VDVGNSRDAEEREEIRRMHEIMDHYQLDGQL





RWVGALLDKTVAGELYRVVADGRGVFVQPA





LFEAFGLTVIEAMSSGLPVFATRFGGPLEIIED





GVSGFHIDPNDHEATAERLADFLEAARERPK





YWLEISDAALARVAERYTWERYAERLMTIAR





IFGFWRFVLDRESQVMERYLQMFRHLQWRPL





AHAVPME





17
P30298.2

Oryza sativa

MAAKLARLHSLRERLGATFSSHPNELIALFSR





Japonica Group

YVNQGKGMLQRHQLLAEFDALIEADKEKYA





PFEDILRAAQEAIVLPPWVALAIRPRPGVWDY





IRVNVSELAVEELSVSEYLAFKEQLVDGHTNS





NFVLELDFEPFNASFPRPSMSKSIGNGVQFLN





RHLSSKLFQDKESLYPLLNFLKAHNHKGTTM





MLNDRIQSLRGLQSSLRKAEEYLMGIPQDTPY





SEFNHRFQELGLEKGWGDCAKRVLDTIHLLL





DLLEAPDPANLEKFLGTIPMMFNVVILSPHGY





FAQSNVLGYPDTGGQVVYILDQVRALENEML





LRIKQQGLDITPKILIVTRLLPDAVGTTCGQRV





EKVIGTEHTDILRVPFRSENGILRKWISRFDV





WPFLETYTEDVANEIMREMQAKPDLIIGNYS





DGNLVATLLAHKLGVTQCTIAHALEKTKYPN





SDIYLDKFDSQYHFSCQFTADLIAMNHTDFIIT





STFQEIAGSKDTVGQYESHIAFTLPGLYRVVH





GIDVFDPKFNIVSPGADMSVYFPYTEADKRLT





AFHPEIEELLYSEVENDEHKFVLKDKNKPIIFS





MARLDRVKNMTGLVEMYGKNAHLRDLANL





VIVCGDHGNQSKDREEQAEFKKMYGLIDQY





KLKGHIRWISAQMNRVRNGELYRYICDTKGV





FVQPAFYEAFGLTVIEAMTCGLPTIATCHGGP





AEIIVDGVSGLHIDPYHSDKAADILVNFFEKC





KQDSTYWDNISQGGLQRIYEKYTWKLYSERL





MTLTGVYGFWKYVSNLERRETRRYIEMFYAL





KYRSLASAVPLAVDGESTSK





18
Q820M5.1

Nitrosomonas

MTTIDTLATCTQQNRDAVYTLLRRYFTANRT





europaea ATCC

LLLQSDLREGLLQTEQDCGQSDMLRAFVFRL




19718
QEGIFSSPWAYLALRPEIAKWEFMRIHQEHLIP





EKLTISEFLKFKETVVKGEATESVLEVDFGPF





NRGFPRLKESRSIGQGVIFLNRKLSSEMFSRIE





AGHTSLLHFLGVHAIEGQQLMFSNNSHDIHA





VRNQLRQALEMLETLDGTTPWIELAPKMNQL





GFAPGWGHNANRVAETMNMLMDILEAPSPS





ALEEFLACIPMISRLLILSPHGYFGQDNVLGLP





DTGGQVVYILDQVRALEKEMHDRLQLQGVQ





VEPKILIVTRLIPDAGDTTCNQRLEKVSGCTNT





WILRVPFRKHNGEIIPHWISRFEIWPHLEIFAG





DVEREALAELGGHPDLIIGNYSDGNLVATLLS





RRLGVTQCNIAHALEKTKYLHSDIYWQENED





KYHFSCQYTADLLAMNSADFIVTSTYQEIAGT





REAEGQYESYQAFSMPDLYRVIHGIDLFDPKF





NIVSPGANADIYFPYSDPNRRLHSLIPEIESLIF





DDATNLPARGYLQDPDKPLIFTMARLDRIKNI





TGLVELYAASPRLRSLANLVIVGGKIDPQHSS





DHEEQEQIHRMHQLMDEHELDQQVRWLGM





RLDKNLAGELYRYIADKRGIFVQPALFEAFGL





TIIEAMASGLPTFATRYGGPLEIIQNNRSGFHI





DPNQGAATADLIADFFEKNLENPQEWERISQ





GALDRVASRYTWKLYAERMMTLSRIYGFWK





FVSGLEREETDRYLNMFYHLQFRPLANRLAH





EI





19
P13708.2

Glycine max

MATDRLTRVHSLRERLDETLTANRNEILALLS





RIEAKGKGILQHHQVIAEFEEIPEENRQKLTDG





AFGEVLRSTQEAIVLPPWVALAVRPRPGVWE





YLRVNVHALVVEELQPAEYLHFKEELVDGSS





NGNFVLELDFEPFNAAFPRPTLNKSIGNGVQF





LNRHLSAKLFHDKESLHPLLEFLRLHSVKGKT





LMLNDRIQNPDALQHVLRKAEEYLGTVPPET





PYSEFEHKFQEIGLERGWGDNAERVLESIQLL





LDLLEAPDPCTLETFLGRIPMVFNVVILSPHGY





FAQDNVLGYPDTGGQVVYILDQVRALENEM





LHRIKQQGLDIVPRILIITRLLPDAVGTTCGQR





LEKVFGTEHSHILRVPFRTEKGIVRKWISRFEV





WPYLETYTEDVAHELAKELQGKPDLIVGNYS





DGNIVASLLAHKLGVTQCTIAHALEKTKYPES





DIYWKKLEERYHFSCQFTADLFAMNHTDFIIT





STFQEIAGSKDTVGQYESHTAFTLPGLYRVVH





GIDVFDPKFNIVSPGADQTIYFPHTETSRRLTS





FHPEIEELLYSSVENEEHICVLKDRSKPIIFTMA





RLDRVKNITGLVEWYGKNAKLRELVNLVVV





AGDRRKESKDLEEKAEMKKMYGLIETYKLN





GQFRWISSQMNRVRNGELYRVICDTRGAFVQ





PAVYEAFGLTVVEAMTCGLPTFATCNGGPAE





IIVHGKSGFHIDPYHGDRAADLLVDFFEKCKL





DPTHWDKISKAGLORIEEKYTWQIYSQRLLTL





TGVYGFWKHVSNLDRRESRRYLEMFYALKY





RKLAESVPLAAE





20
CAA09297.1

Nostoc sp. PCC

MSELMQAILDSEEKHDLRGFISELRQQDKNY





7119

LLRNDILNVYAEYCSKCQKPETSYKESNLSKL





IYYTQEIIPEDSNFCFIIRPKIAAQEVYRLTADL





DVEPMTVQELLDLRDRLVNKFHPYEGDILEL





DFGPFYDYTPTIRDPKNIGKGVQYLNRYLSSK





LFQDSQQWLESLFNFLRLHNYNGIQLLINHQI





QSQQQLSQQVKNALNFVSDRPNDEPYEQFRL





QLQTMGFEPGWGNTASRVRDTLNILDELIDSP





DPQTLEAFISRIPMIFRIVLVSAHGWFGQEGVL





GRPDTGGQVVYVLDQAKNLEKQLQEDAILA





GLEVLNVQPKVIILTRLIPNSDGTLCNQRLEK





VYGTENAWILRVPLREFNPKMTQNWISRFEF





WPYLETFAIDSERELLAEFQGRPDLIVGNYTD





GNLVAFLLTRRMKVTQCNIAHALEKSKYLFS





NLYWQDLEEKYHFSLOFTADLIAMNAANFVI





SSTYQEIVGTPDSIGQYESYKCFTMPELYHVV





NGIELFSPKFNVVPPGVNENSYFPYTQTQNRIE





SDRDRLEEMLFTLEDSSQIFGKLDDPNKRPIFS





MARLDRIKNLTGLAECFGQSQELQERCNLILV





AGKLRIEESEDNEEKDEIVKLYRIIDEYNLHG





KIRWLGVRLSKNDSGEIYRVICDRQGIFVQPA





LFEAFGLTILESMISGLPTFATQFGGPLEIIQDK





INGFYINPTHLEETATKILDFVTKCEQNPNYW





NIISEKAIDRVYSTYTWKIHTTKLLTLARIYGF





WNFTSKEKREDLLRYLESLFYLIYKPRAQQLL





EQHKYR





21
P49036.1

Zea mays

MGEGAGDRVLSRLHSVRERIGDSLSAHPNEL





VAVFTRLKNLGKGMLQPHQIIAEYNNAIPEAE





REKLKDGAFEDVLRAAQEAIVIPPWVALAIRP





RPGVWEYVRVNVSELAVEELRVPEYLQFKEQ





LVEEGPNNNFVLELDFEPFNASFPRPSLSKSIG





NGVQFLNRHLSSKLFHDKESMYPLLNFLRAH





NYKGMTMMLNDRIRSLSALQGALRKAEEHL





STLQADTPYSEFHHRFQELGLEKGWGDCAKR





AQETIHLLLDLLEAPDPSTLEKFLGTIPMVFNV





VILSPHGYFAQANVLGYPDTGGQVVYILDQV





RAMENEMLLRIKQCGLDITPKILIVTRLLPDAT





GTTCGQRLEKVLGTEHCHILRVPFRTENGIVR





KWISRFEVWPYLETYTDDVAHEIAGELQANP





DLIIGNYSDGNLVACLLAHKMGVTHCTIAHA





LEKTKYPNSDLYWKKFEDHYHFSCQFTTDLI





AMNHADFIITSTFQEIAGNKDTVGQYESHMA





FTMPGLYRVVHGIDVFDPKFNIVSPGADLSIY





FPYTESHKRLTSLHPEIEELLYSQTENTEHKFV





LNDRNKPIIFSMARLDRVKNLTGLVELYGRN





KRLQELVNLVVVCGDHGNPSKDKEEQAEFK





KMFDLIEQYNLNGHIRWISAQMNRVRNGELY





RYICDTKGAFVQPAFYEAFGLTVVEAMTCGL





PTFATAYGGPAEIIVHGVSGYHIDPYQGDKAS





ALLVDFFDKCQAEPSHWSKISQGGLQRIEEKY





TWKLYSERLMTLTGVYGFWKYVSNLERRET





RRYLEMLYALKYRTMASTVPLAVEGEPSSK





22
P49040.3

Arabidopsis

MANAERMITRVHSQRERLNETLVSERNEVLA





thaliana

LLSRVEAKGKGILQQNQIIAEFEALPEQTRKK





LEGGPFFDLLKSTQEAIVLPPWVALAVRPRPG





VWEYLRVNLHALVVEELQPAEFLHFKEELVD





GVKNGNFTLELDFEPFNASIPRPTLHKYIGNG





VDFLNRHLSAKLFHDKESLLPLLKFLRLHSHQ





GKNLMLSEKIQNLNTLQHTLRKAEEYLAELK





SETLYEEFEAKFEEIGLERGWGDNAERVLDMI





RLLLDLLEAPDPCTLETFLGRVPMVFNVVILS





PHGYFAQDNVLGYPDTGGQVVYILDQVRAL





EIEMLQRIKQQGLNIKPRILILTRLLPDAVGTT





CGERLERVYDSEYCDILRVPFRTEKGIVRKWI





SRFEVWPYLETYTEDAAVELSKELNGKPDLII





GNYSDGNLVASLLAHKLGVTQCTIAHALEKT





KYPDSDIYWKKLDDKYHFSCQFTADIFAMNH





TDFIITSTFQEIAGSKETVGQYESHTAFTLPGL





YRVVHGIDVFDPKFNIVSPGADMSIYFPYTEE





KRRLTKFHSEIEELLYSDVENKEHLCVLKDKK





KPILFTMARLDRVKNLSGLVEWYGKNTRLRE





LANLVVVGGDRRKESKDNEEKAEMKKMYD





LIEEYKLNGQFRWISSQMDRVRNGELYRYIC





DTKGAFVQPALYEAFGLTVVEAMTCGLPTFA





TCKGGPAEIIVHGKSGFHIDPYHGDQAADTLA





DFFTKCKEDPSHWDEISKGGLQRIEEKYTWQI





YSQRLLTLTGVYGFWKHVSNLDRLEARRYLE





MFYALKYRPLAQAVPLAQDD





23
Q9M111.1

Arabidopsis

MANPKLTRVLSTRDRVQDTLSAHRNELVALL





thaliana

SRYVDQGKGILQPHNLIDELESVIGDDETKKS





LSDGPFGEILKSAMEAIVVPPFVALAVRPRPG





VWEYVRVNVFELSVEQLTVSEYLRFKEELVD





GPNSDPFCLELDFEPFNANVPRPSRSSSIGNGV





QFLNRHLSSVMFRNKDCLEPLLDFLRVHKYK





GHPLMLNDRIQSISRLQIQLSKAEDHISKLSQE





TPFSEFEYALQGMGFEKGWGDTAGRVLEMM





HLLSDILQAPDPSSLEKFLGMVPMVFNVVILS





PHGYFGQANVLGLPDTGGQVVYILDQVRALE





TEMLLRIKRQGLDISPSILIVTRLIPDAKGTTCN





QRLERVSGTEHTHILRVPFRSEKGILRKWISRF





DVWPYLENYAQDAASEIVGELQGVPDFIIGN





YSDGNLVASLMAHRMGVTQCTIAHALEKTK





YPDSDIYWKDFDNKYHFSCQFTADLIAMNNA





DFIITSTYQEIAGTKNTVGQYESHGAFTLPGLY





RVVHGIDVFDPKFNIVSPGADMTIYFPYSEET





RRLTALHGSIEEMLYSPDQTDEHVGTLSDRSK





PILFSMARLDKVKNISGLVEMYSKNTKLRELV





NLVVIAGNIDVNKSKDREEIVEIEKMHNLMK





NYKLDGQFRWITAQTNRARNGELYRYIADTR





GAFAQPAFYEAFGLTVVEAMTCGLPTFATCH





GGPAEIIEHGLSGFHIDPYHPEQAGNIMADFFE





RCKEDPNHWKKVSDAGLQRIYERYTWKIYSE





RLMTLAGVYGFWKYVSKLERRETRRYLEMF





YILKFRDLVKTVPSTADD





24
Q8W517

Ipomoea batatas

MAGNDWINSYLEAILDVGPGIDDAKSSLLLRE





RGRFSPTRYFVEEVITGFDETDLHRSWVRAQ





ATRSPQERNTRLENMCWRIWNLARQKKQLE





GEQAQRLAKRRQERERGRREAVADMSEDLS





EGEKGDAISDISAHGESIKGRLPRISSVETMES





WANQQKGKKLYIVLISLHGLIRGENMELGRD





SDTGGQVKYVVELARALGSMPGVYRVDLLT





RQVSSPEVDWSYGEPTEMLTPINSEGLMTEM





GESSGAYIIRIPFGPRDKYIPKEDLWPYIPEFVD





GALNHILHVSKVLGGQIGSGRDVWPVAIHGH





YADAGDSAALLSGALNVPMLFTGHSLGRDK





LEQLLRQGRLSKDEINSTYKIMRRIEAEELSLD





ASEIVITSTRQEIDEQWRLYDGFDPILERKLRA





RIKRNVSCYGRFMPRMVVIPPGMEFHHIVPHE





GDMDFETEGSEDGKAPDPHIWTEIMRFFSNPR





KPMILALARPDPKKNLTTLVKAFGECRPLREL





ANLTLIMGNRDNIDEMSSTNASVLLSILKMID





KYDLYGQVAYPKHHKQSEVPDIYRLAAKTK





GVFINPAFIEPFGLTLIEAAAHGLPIVATKNGG





PVDIHRGSDNGLLVDPHDQHAIADALLKLVA





DKHLWAKCRANGLKNIHLFSWPEHCKTYLS





RIAGCKPRQPCWLRNADDDENSESESPSDSLR





DIQDISLNLKFSLDGDKNEDSDNLFDPDDRKN





KLENAVLAWSKGVKGTHKTSIDKIDQSSSAG





KFPALRRRKQIFVIAVDCDSSTGLFENVRKIFA





AVEAEGMEGSIGFHIGHFIQYIRSAFFSDFRGH





ESTDFDAFICNSGGDLYYSSSHSEDNPFVVDL





YYHSHIEYRWGGEGLRKTLVRWAASISDKKG





EKEEHIVVEDEKNSADYCYTFKVQKSGGDPS





VKELRKSMRIQALRCHVVYCQNGSRINVIPVL





SSRSQALRYLYLRWGMDLSKLVVFVGESGDT





DYEGLLGGLRKAVILKGVCSVSSSQLLSNRN





YPLTDVVPYNSPNVIQTTEECSSSELHASLEKL





AVLKG





25
WP_011056890

Thermosynechococcus

MTCVLLKAVVESDERADLRQFSRILQLGEKR





elongatus

YLLRNDILDAFADYCRDQERPVPPPSESRLSK





LVFYTQEIIVDNESLCWIVRPRIAQQEVCRLLV





EDLTIVPMTIPELLDLRDRLVNHYHPNEGDVF





EIDVQPFYDYSPIIRDAKNIGKGVEFLNRYLSS





KLFQDPRQWQQNLFNFLRIHRYNGYQLLINE





RIRSPQHLSEQVKQALVVLSDRPPTEAYSEFR





FELQNLGFEPGWGNTVARVRDTLEILDQLLD





SPDHQVLEAFVSRIPMLFRIALISPHGWFGQE





GVLGRPDTGGQVVYILDQVKSLEKQMREDLE





LAGLGVLEAQPKIIVLTRLIPNAEGTLCNQRLE





KIYGTNDAWILRVPFREFNPKVTQNWISRFEI





WPYLETFAIDAERELRAEFGHVPDLIIGNYSD





GNLVAFLLARRLKVTQCNIAHALEKSKYLFS





NLYWQDLEDKYHFSLOFTADLIAMNAANFIIS





STYQEIVGTPDSIGQYESYQSFTMPDLYHVVN





GIELFSPKFNVVPPGVNEQVYFPYYHYTERLE





GDRQRLEELLFTLEDPQQIYGYLEAPEKRPLF





SMARLDRIKNLTGLAEAFGRSKALQERCNLIL





VAGKLRTADSSDREEIAEIEKLYQIIHQYNLH





GKIRWLGIRLPKADSGEIYRIIADRQGIFVQPA





LFEAFGLTILEAMISGLPTFGTRFGGPLEIIQDG





VNGFYINPTHLEEMAETIVRFLEACDRDPQE





WQRISKAGIERVYSTYTWKIHCTRLLSLAKIY





GFWNFSSQENREDMMRYMEALFHLLYKPRA





QALLAEHLQR









Table 8 provides exemplary sequences for enzymes involved in generation and/or recycling of UDP-glucose the reaction intermediates in accordance with the methods of invention.












TABLE 8





SEQ





ID





NO
Gene
Accession
Sequence







26
GLK
AAA27694.1
MEIVAIDIGGTHARFSIAEVSNGRVLSLGEETTFKTAEHASLQ





LAWERFGEKLGRPLPRAAAIAWAGPVHGEVLKLTNNPWVL





RPATLNEKLDIDTHVLINDFGAVAHAVAHMDSSYLDHICGP





DEALPSDGVITILGPGTGLGVAHLLRTEGRYFVIETEGGHIDF





APLDRLEDKILARLRERFRRVSIERIISGPGLGNIYEALAAIEG





VPFSLLDDIKLWQMALEGKDNLAEAALDRFCLSLGAIAGDL





ALAQGRTSVVIGGGVGLRIASHLPESGFRQRFVSKGRFERV





MSKIPVKLITYPQPGLLGAQLPMPTNILKLNNIF





27
GLK
WP_331012003.1
MEIVAVDIGGTHARFAIAEVGDGHVLSLGEPVTLKTAEHGS





LQLAWEAAGEALGRPIPRAAGIAIATPIGGEVLKLTNNPWVI





RPALIQSKLGVDSYVLVNDFEAVGHAVAQVGAEYLQHLCG





PDDPLPDTGIITIVGPGTGLGVAHLLKTPAGYHVLPCEGGHI





DFAPLDVLEDGILKTLRKQYRRVSVERIVSGPGLVNIYESLPP





STSAALRPIDDKELWTAALAGTDSRAAAALDRFCLSLGAVA





GDLALAHGAKAVVIAGGLGLRIADHLPRSGFSERFVAKGRF





ERIMSAMPVKFITHPQPGLFGAAAAFAGAHRS





28
PGM
AAC73782.1
MAIHNRAGQPAQQSDLINVAQLTAQYYVLKPEAGNAEHAV





KFGTSGHRGSAARHSFNEPHILAIAQAIAEERAKNGITGPCY





VGKDTHALSEPAFISVLEVLAANGVDVIVQENNGFTPTPAVS





NAILVHNKKGGPLADGIVITPSHNPPEDGGIKYNPPNGGPAD





TNVTKVVEDRANALLADGLKGVKRISLDEAMASGHVKEQD





LVQPFVEGLADIVDMAAIQKAGLTLGVDPLGGSGIEYWKRI





GEYYNLNLTIVNDQVDQTFRFMHLDKDGAIRMDCSSECAM





AGLLALRDKFDLAFANDPDYDRHGIVTPAGLMNPNHYLAV





AINYLFQHRPQWGKDVAVGKTLVSSAMIDRVVNDLGRKLV





EVPVGFKWFVDGLFDGSFGFGGEESAGASFLRFDGTPWSTD





KDGIIMCLLAAEITAVTGKNPQEHYNELAKRFGAPSYNRLQ





AAATSAQKAALSKLSPEMVSASTLAGDPITARLTAAPGNGA





SIGGLKVMTDNGWFAARPSGTEDAYKIYCESFLGEEHRKQI





EKEAVEIVSEVLKNA





29
PGM
A0A110EI47
MAKHPRAGQQPTSCDLINVAKLTSQYYVLQPALHESAHAV





KFGTSGHRGSSTKHTFNEAHILAIAQAIAEIRHAKGITGPCYV





GKDTHALSEPAFISVLEVLAANQVTVIIQPENGFTPTPAISHAI





LTHNKSNPIHLADGIVITPSHNPPEDGGIKYNPPNGGPADTDF





TGLIEKRANQLLDERSSENAVLAGVKRISLSQAISSQFIIQQD





MMMPYVEDLVNVVDLSVIQQAGLKLGVDPLGGSGIAYWQ





QIAEYYKLNLSLVNDQVDQTFRFMPLDHDGVIRMDCSSVD





AMGGLLRLKDKFDLAFANDPDYDRHGIVTPAGLMNPNHYL





SVAINYLYQNRPGWPVDLGVGKTLVSSAMIDRVVSSLNRKL





VEVPVGFKWFVDGLYTGKLGFGGEESAGASFLRFDAKPWS





TDKDGIIMCLLSAEITARTGKNPQVHYDELSEKFGAPIYNRI





QANATHEQKAILSKLSPDQVQAKTLAGDLITARITHAPSNN





ASIGGLKVVTDNGWFAARPSGTEEAYKIYCESFISHEHLDLI





SKEAVEIVDAAFASNK





30
PGM
A0A7M2S2U2
MAMHPRAGQKAQQEDLHNIPALVANYFLLQPDAANAEHK





VQFGTSGHRGTADKHTFNENHILAIAQAVAEVRSEQGTTGP





LFVGKDTHALSEPAFSSVIEVLIANGVKVIVQQDNGYTPTPG





ISHAILTYNIKHDEKADGIVITPSHNPPQDGGIKYNPTHGGPA





EAELTQAIEDRANELIAEGLQGVKRLPLAEAKASDLFVEMD





LVKPYIDDLVNVIDMEAIQKANLKIGVDPLGGSGIDYWRQI





GQAYNLDLTLVSEAIDPSFQFMSLDKDGVVRMDCSSPYAM





AGLLALKDEYDLAFGNDPDYDRHGIVTPKGLMNPNHFLAV





CIDYLYRHRDAWGKDVAVGKTLVSSALIDRVVADLGRALC





EVPVGFKWFVDGLYTGKFGFGGEESAGASFLRKDGTPWST





DKDGILLCLLAAEITAVTGKNPQDYYEELAAKHGESKYNRI





QAVANGPQKDVLKKLSPEMVAAETLAGDAITARLTHAPGN





GAAIGGLKVTTANGWFAARPSGTEDIYKIYCESFKGEEHLK





QIEAEAQEIVNQVFAAAGL





31
UGP
EEW2752841.1
MAAINTKVKKAVIPVAGLGTRMLPATKAIPKEMLPLVDKPL





IQYVVNECIAAGITEIVLVTHSSKNSIENHFDTSFELEAMLEK





RVKRQLLDEVQSICPPHVTIMQVRQGLAKGLGHAVLCAHP





VVGDEPVAVILPDVILDEYESDLSQDNLAEMIRRFDETGHSQ





IMVEPVADVTAYGVVDCKGVELAPGESVPMVGVVEKPKA





DVAPSNLAIVGRYVLSADIWPLLAKTPPGAGDEIQLTDAIDM





LIEKETVEAYHMKGKSHDCGNKLGYMQAFVEYGIRHNTLG





TEFKAWLEEEMGIKK





32
UGP
WP_021648042.1
MFAEDLKRTEKMTVDDVFEQSAQKMREQGMSEIAISQFRH





AYHVWASEKESAWIREDTVEPLHGVRSFHDVYKTIDHDKA





VHAFAKTAFLKLNGGLGTSMGLQCAKSLLPVRRHKARQMR





FLDIILGQVLTARTRLNVPLPVTFMNSFRTSDDTMKALRHQR





KFKQTDIPLEIIQHQEPKIDAATGAPASWPANPDLEWCPPGH





GDLFSTLRESGLLDTLLEHGFEYLFISNSDNLGARPSRTLAQ





YFEDTGAPFMVEVANRTYADRKGGHIVRDTATGRLILREMS





QVHPDDKDAAQDIAKHPYFNTNNIWVRIDVLRDMLAEHDG





VLPLPVIINNKTVDPIDPQSPAVVQLETAMGAAIGLFEGAICV





QVDRMRFLPVKTTNDLFIMRSDRFHLTDSYEMEDGNYIFPN





VDLDPRYYKNIEDFNERFPYNVPSLAAANSVSIKGDWTFGR





DVIMFADARLEDRNEPSYVPNGEYVGPMGIEPGDWV





33
UGP
WP_028847555.1
MTASAEHQTFTTAIVPAAGLGTRFLPTTKSVPKELLPVVDTP





AIELVADEARQAGAERLVIVTSPAKQSIAAYFRPAPELERSL





EEKGKTGQLAKIRRAPELLEVEVAIQEQALGLGHAVACAEP





NLGPEDDVVAVLLPDDLVLPHGILERMAKVRAEHGGSVLC





AFDIPKEEISAYGVFDVSDTDDADVKRVHGMVEKPPAEQAP





STFAAAGRYLLDRAIFDALRRIEPGAGGELQLTDAVALLIQE





GHPVHVVVHRGDRHDLGNPGGFLRAAVDFALQDPDYGPEL





RAWLTDRIARP





34
NDK
WP_000963837.1
MAIERTFSIIKPNAVAKNVIGNIFARFEAAGFKIVGTKMLHLT





VEQARGFYAEHDGKPFFDGLVEFMTSGPIVVSVLEGENAVQ





RHRDLLGATNPANALAGTLRADYADSLTENGTHGSDSVES





AAREIAYFFGEGEVCPRTR





35
NDK
CAF21035.1
MTERTLILIKPDGVTNGHVGEIIARIERKGLKLAALDLRVAD





RETAEKHYEEHADKPFFGELVEFITSAPLIAGIVEGERAIDA





WRQLAGGTDPVAKATPGTIRGDFALTVGENVVHGSDSPES





AEREISIWFPNL





36
NDK
WP_066795798
MTERTLILIKPDGVANGHVGEIIARIERKGLKLVELDLRTAD





RETAEKHYEEHSDKPFFGELVEFITSAPLVAGIVEGERAIDA





WRQLAGGTDPVSKATPGTIRGDFALTVGENVVHGSDSPESA





EREIAIWFPNK





37
PPK2
WP_010968631
MALDEAPAEARPGSRAVELEIDGRSRIFDIDDPDLPKWIDEE





AFRSDDYPYKKKLDREEYEETLTKLQIELVKVQFWMQATG





KRVMAVFEGRDAAGKGGAIHATTANMNPRSARVVALTKP





TETERGQWYFQRYVATFPTAGEFVLFDRSWYNRAGVEPVM





GFCTPDQYEQFLKEAPRFEEMIANEGIHLFKFWINIGREMQL





KRFHDRRHDPLKIWKLSPMDIAALSKWDDYTGKRDRMLKE





THTEHGPWAVIRGNDKRRSRINVIRHMLTKLDYDGKDEAAI





GEVDEKILGSGPGFLR





38
PPK2
WP_160857702
MVEKAESRAVELDIDGKKRVFDIDDPKLPDWIDKEAFQSDD





FPYDKKLDEDEYEEALEALQVELVKVQFWQQKTGARIMAI





FEGRDAAGKGGAIHATMSNMNPRSARIVALTKPTETEQGQ





WYFQRYVATFPTSGEFVLFDRSWYNRAGVEPVMGFCTPEQ





YEKFLKATPRIEKMIASEGIHFFKFWLNIGREMQLKRFHDRR





HDPLKVWKLSPMDIAALNKWDDYTEKRDRMLKATHTDRA





PWTVIRANDKRRARINLIRHILTTLDYEGKDEKAIGKIDDKIV





GSGPGFVK









INCORPORATION BY REFERENCE

References and citations to other documents, such as patents, patent applications, patent publications, journals, books, papers, web contents, publicly accessible databases, have been made throughout this disclosure. All such documents are hereby incorporated herein by reference in their entirety for all purposes.


EQUIVALENTS

Various modifications of the invention and many further embodiments thereof, in addition to those shown and described herein, will become apparent to those skilled in the art from the full contents of this document, including references to the scientific and patent literature cited herein. The subject matter herein contains important information, exemplification and guidance that can be adapted to the practice of this invention in its various embodiments and equivalents thereof.

Claims
  • 1. A method for cell-free production of carminic acid, wherein the method comprises: providing one or more enzymes in a cell-free medium, wherein the one or more enzymes result in transformation of one or more substrates to carminic acid.
  • 2. The method of claim 1, wherein the substrate is kermesic acid.
  • 3. The method of claim 2, wherein the enzyme is C-glucosyltransferase (CGT).
  • 4. The method of claim 2, further comprising the cell-free medium comprises an activated sugar.
  • 5. The method of claim 4, wherein the activated sugar is UDP-glucose.
  • 6. The method of claim 5, wherein the UDP-glucose is added to the cell-free medium.
  • 7. The method of claim 5, wherein the UDP-glucose is synthesized in the cell-free medium by the one or more enzymes.
  • 8. The method of claim 7, wherein the UDP-glucose is synthesized from one or ingredients selected from the group consisting of: sucrose, glucose, UTP, UDP, ATP, glucose-6-phosphate, glucose-1-phosphate, and/or polyphosphate.
  • 9. The method of claim 8, wherein the one or more enzymes is selected from the group consisting of sucrose synthase (SuSy), glucokinase (GLK), hexokinase (HK), phosphoglucomutase (PGM), polyphosphate kinase (PPK), UTP-glucose-1-phosphate uridylyltransferase (UGP), and nucleoside diphosphate kinase (NDK).
  • 10. The method of claim 1, wherein the cell-free medium is a cell lysate.
  • 11. The method of claim 10, wherein the cell lysate is a cell lysate from cells from a host organism expressing the one or more enzymes.
  • 12. The method of claim 11, wherein the host organism is selected from a group consisting of: bacteria, yeast, and/or mammalian cells.
  • 13. The method of claim 11, wherein the one or more enzymes are introduced in the host organism by integration into genome of the host organism or on a plasmid.
  • 14. The method of claim 13, wherein the host organisms expressing the one or more enzymes are cultured until a pre-determined biomass is achieved to produce the requisite quantity of the one or more enzymes.
  • 15. The method of claim 14, further comprising lysing of cells followed by removal of cell debris to generate a cell lysate for use in the cell-free medium for cell-free production of carminic acid.
  • 16. The method of claim 15, wherein the one or enzymes are selected from the group consisting of CGT, SuSy, GLK, HK, PGM, PPK, UGP, and NDK.
  • 17. The method of claim 16, wherein the one or more enzymes are present in the cell-free medium for cell-free production of carminic acid.
  • 18. The method of claim 16, wherein the method does not include separating and/or purifying one more enzymes for cell-free production of carminic acid.
  • 19. The method of claim 18, wherein the cell-free medium further comprises: buffer, kermesic acid, an activated sugar, magnesium chloride, cell lysate, sucrose, glucose, glucose-1-phosphate, glucose-6-phosphate, UDP, UTP, ATP, polyphosphate, and/or water.
  • 20. (canceled)
  • 21. (canceled)
  • 22. The method of claim 18, wherein the method results in titer value of produced carminic acid is from about 10 times to about 5000 times higher than methods for cell-based production of carminic acid.
  • 23.-74. (canceled)
Provisional Applications (1)
Number Date Country
63523725 Jun 2023 US